PRODUCT MONOGRAPH
INCLUDING PATIENT MEDICATION INFORMATION

PrCLOZARIL®
Clozapine Tablets
25 mg, 50 mg, 100 mg and 200 mg

Antipsychotic Agent

HLS Therapeutics Inc.
10 Carlson Court, Suite 701
Etobicoke, Ontario M9W 6L2

Date of Initial Authorization:
April 06, 2016

Date of Revision:
May 31, 2021

Submission Control No: 247538

CLOZARIL® is a registered trademark of Novartis Pharmaceuticals Corporation.
## RECENT MAJOR LABEL CHANGES

<table>
<thead>
<tr>
<th>Category</th>
<th>Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>7 WARNINGS AND PRECAUTIONS, Skin</td>
<td>05/2021</td>
</tr>
<tr>
<td>7 WARNINGS AND PRECAUTIONS, 7.1.4 Geriatrics</td>
<td>05/2021</td>
</tr>
<tr>
<td>7 WARNINGS AND PRECAUTIONS, General, Anticholinergic Activity</td>
<td>01/2020</td>
</tr>
<tr>
<td>Section</td>
<td>Page</td>
</tr>
<tr>
<td>-----------------------------------------</td>
<td>------</td>
</tr>
<tr>
<td>STORAGE, STABILITY AND DISPOSAL</td>
<td>33</td>
</tr>
<tr>
<td>SPECIAL HANDLING INSTRUCTIONS</td>
<td>33</td>
</tr>
<tr>
<td>PART II: SCIENTIFIC INFORMATION</td>
<td>34</td>
</tr>
<tr>
<td>PHARMACEUTICAL INFORMATION</td>
<td>34</td>
</tr>
<tr>
<td>14 CLINICAL TRIALS</td>
<td>34</td>
</tr>
<tr>
<td>14.1 Trial Design and Study Demographics</td>
<td>34</td>
</tr>
<tr>
<td>14.2 Study Results</td>
<td>35</td>
</tr>
<tr>
<td>MICROBIOLOGY</td>
<td>36</td>
</tr>
<tr>
<td>NON-CLINICAL TOXICOLOGY</td>
<td>36</td>
</tr>
<tr>
<td>PATIENT MEDICATION INFORMATION</td>
<td>40</td>
</tr>
</tbody>
</table>
PART I: HEALTH PROFESSIONAL INFORMATION

1 INDICATIONS

CLOZARIL® (clozapine) tablet is indicated in the management of symptoms of treatment-resistant schizophrenia. In controlled clinical trials, clozapine was found to improve both positive and negative symptoms.

Due to the significant risk of neutropenia and seizure associated with its use, clozapine should be limited to treatment-resistant schizophrenic patients who are non-responsive to, or intolerant of, conventional antipsychotic drugs. Non-responsiveness is defined as the lack of satisfactory clinical response, despite treatment with appropriate courses of at least two marketed chemically-unrelated antipsychotic drugs. Intolerance is defined as the inability to achieve adequate benefit with conventional antipsychotic drugs because of dose-limiting, intolerable adverse effects.

Because of the significant risk of neutropenia and seizure, events which both present a continuing risk over time, the extended treatment of patients failing to show an acceptable level of clinical response to clozapine should ordinarily be avoided. Seizure risk is dose-related and is more likely to occur with rapid dose increases. Titrate gradually and use divided doses. Use with caution in patients with history of seizure or risk factors for seizure.

Clozapine can be used only if regular hematological examinations can be guaranteed, as specified under 7 WARNINGS AND PRECAUTIONS, Hematologic and 4 DOSAGE AND ADMINISTRATION.

CLOZARIL® is available only through a distribution system the Clozaril Support and Assistance Network® (“CSAN”) that ensures weekly, every-two-week or every-four-week hematological testing prior to the dispensing of the next period's supply of CLOZARIL® (see 7 WARNINGS AND PRECAUTIONS, Hematologic).

This requires:

- registration of the patient, their current location, treating physician, testing laboratory and dispensing pharmacist in the CSAN system.
- maintenance of a national HLS Therapeutics monitoring system of the hematological results of all patients on CLOZARIL® and provides timely feedback (within 24 hours of receipt of the blood test results) to the treating physician and dispensing pharmacist/or pharmacy
- the ability to identify patients who have been assigned "Non-rechallengeable Status" (see 7 WARNINGS AND PRECAUTIONS). This requires that HLS Therapeutics both provide to, and obtain from, all other approved suppliers† of clozapine, the Non-rechallengeable Status / Hematological Status of all patients (see 4 DOSAGE AND ADMINISTRATION). HLS Therapeutics must be able to provide this information within 24 hours of receiving a written request.

Physicians should not prescribe CLOZARIL® until the non-rechallengeable status and the hematological status of the patient has been verified.

† “approved supplier” is a manufacturer who holds a valid Notice of Compliance (NOC) for clozapine
For the distribution system to be effective, treating physicians must ensure that the hematological testing is performed at the required frequency (see 7 WARNINGS AND PRECAUTIONS, Hematologic) and that arrangements are made for the hematological results to be sent to CSAN. Physicians may obtain details on the CSAN distribution system by calling a toll-free phone number 1 (800) 267-2726.

Other monitoring and distribution systems
Between 1991 and 2003, clozapine was distributed by a single manufacturer, and patients were monitored by this manufacturer’s specific registry and distribution system. The introduction of clozapine from other manufacturers has now resulted in the establishment of manufacturer-specific registry and distribution systems.

In order to ensure the safe use and continued monitoring of all patients taking clozapine, the physician must have obtained consent from the patient for the potential sharing of hematological and other safety data between clozapine registries.

Patients may not be switched from one brand of clozapine to another without the completion of a new registry-specific patient registration form signed by the prescribing physician.

If a patient is switched from one brand of clozapine to another, the frequency of hematological monitoring may continue unaltered unless a change is clinically indicated.

1.1 Pediatrics

Pediatrics (< 18 years of age): No pediatric studies have been performed. The safety and efficacy of CLOZARIL® in children and adolescents have not been established. No data are available to Health Canada; therefore, Health Canada has not authorized an indication for pediatric use.

1.2 Geriatrics

Geriatrics (>60 years of age): See 3 SERIOUS WARNINGS AND PRECAUTIONS BOX and 7.1.4 Geriatrics. CLOZARIL® should be used with care in the elderly (see 4.2 Recommended Dose and Dosage Adjustment, Dosing Considerations in Special Populations.

2 CONTRAINDICATIONS

- CLOZARIL® (clozapine) is contraindicated in patients who are hypersensitive to clozapine or to any ingredient in the formulation, including any non-medicinal ingredient, or component of the container. For a complete listing, see 6 DOSAGE FORMS, STRENGTHS, COMPOSITION AND PACKAGING.

- Patients with myeloproliferative disorders, a history of toxic or idiosyncratic agranulocytosis or severe granulocytopenia (with the exception of granulocytopenia/agranulocytosis from previous chemotherapy). [Clozapine should not be used simultaneously with other agents known to suppress bone marrow function].

- Patients with active liver disease associated with nausea, anorexia, or jaundice; progressive liver disease; hepatic failure.
• Patients unable to undergo blood tests.

Other contraindications include severe central nervous system depression or comatose states, severe renal or cardiac disease (e.g., myocarditis), paralytic ileus, uncontrolled epilepsy.

3 SERIOUS WARNINGS AND PRECAUTIONS BOX

<table>
<thead>
<tr>
<th>Serious Warnings and Precautions</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Severe Neutropenia (Agranulocytosis)</strong></td>
</tr>
<tr>
<td>CLOZARIL treatment has caused severe neutropenia, defined as an absolute neutrophil count (ANC) less than 500/µL. Severe neutropenia can lead to serious infection and death. Prior to initiating treatment with CLOZARIL a baseline ANC must be at least 1500/µL for the general population; and must be at least 1000/µL for patients with documented Benign Ethnic Neutropenia (BEN). Regular hematologic monitoring is required prior to dispensing, because of the significant risk of this potentially life-threatening adverse event (see 7 WARNINGS AND PRECAUTIONS, Hematologic). Advise patients to immediately report the appearance of lethargy, weakness, fever, sore throat, flu-like complaints or any other signs of infection.</td>
</tr>
<tr>
<td><strong>Myocarditis and Cardiomyopathy and Mitral Valve Incompetence</strong></td>
</tr>
<tr>
<td>Fatal myocarditis and cardiomyopathy have occurred with the use of CLOZARIL®. Discontinue CLOZARIL® and obtain a cardiac evaluation upon suspicion of myocarditis or cardiomyopathy. Consider the possibility of myocarditis or cardiomyopathy if chest pain, tachycardia, palpitations, dyspnea, fever, flu-like symptoms, hypotension, or ECG changes occur. Generally, patients with a history of clozapine-associated myocarditis or cardiomyopathy should not be rechallenged with CLOZARIL®. (see 7 WARNINGS AND PRECAUTIONS, Cardiovascular)</td>
</tr>
<tr>
<td><strong>Increased Mortality in Elderly Patients with Dementia</strong></td>
</tr>
<tr>
<td>Elderly patients with dementia treated with antipsychotic drugs are at an increased risk of death compared to those treated with placebo (see 7.1.4 Geriatrics). CLOZARIL is not approved for use in elderly patients with dementia.</td>
</tr>
</tbody>
</table>

4 DOSAGE AND ADMINISTRATION

4.1 Dosing Considerations

CLOZARIL® (clozapine) treatment must be initiated on an in-patient basis or in an out-patient setting, where medical supervision is available and vital signs can be monitored for a minimum of 6 to 8 hours after the initial 2 to 3 doses.

When treatment is initiated in out-patients, special caution is advised in patients who are receiving benzodiazepines or other psychotropic drugs as these patients may have an increased risk of circulatory collapse accompanied by respiratory and/or cardiac arrest (see 9.4
Drug-Drug Interactions). Extra caution is advised in patients with cardiovascular disease or a history of seizures (see 7 WARNINGS AND PRECAUTIONS, Cardiovascular and Neurologic).

CLOZARIL® is restricted to patients who have a normal absolute neutrophil count (ANC) and in whom an ANC can be carried out at least weekly for the first 26 weeks of treatment with clozapine, at least at two-week intervals for the next 26 weeks, and at least at four-week intervals thereafter. Monitoring must continue for as long as the patient is on the drug. If the patient is discontinued due to neutropenia, monitoring should be conducted twice a week until ANC is normal (ANC is ≥2.0 x 10⁹/L). In patients with BEN, continue monitoring until their ANC is ≥1.0 x 10⁹/L. For clozapine discontinuation for a reason unrelated to neutropenia, continuation of the existing ANC monitoring is recommended for general population patients until their ANC is ≥2.0 x 10⁹/L (≥1.0 x 10⁹/L for BEN patients) (see 7 WARNINGS AND PRECAUTIONS, Severe Neutropenia, ANC Count Guidelines).

The change from a weekly to a "once every two weeks", or from a “once every two weeks” to a “once every four weeks” schedule should be evaluated on an individual patient basis after 26 and 52 weeks of treatment, respectively. This decision should be made based upon the hematological profile of the patient during the first 26 or 52 weeks of treatment (as appropriate) (see 7 WARNINGS AND PRECAUTIONS, Hematologic), the clinical judgement of the treating physician, and if they deem it appropriate, a consulting hematologist, as well as the patient's willingness to pursue a given frequency of blood monitoring. In turn, the clinical evaluation should take into consideration possible factors that would place the patient in a higher risk group. Weekly hematological testing should be resumed for an additional 6 weeks if therapy is disrupted for more than 3 days. If clozapine is interrupted for 4 weeks or longer, weekly monitoring is required for an additional 26 weeks (See 7 WARNINGS AND PRECAUTIONS, Severe Neutropenia, Monitoring Schedule Guideline).

CLOZARIL® is available only through a distribution system that requires weekly, every-two-week or every-four-week hematological testing prior to the dispensing of the next period's supply of medication (see 1 INDICATIONS).

HLS Therapeutics will provide the Non-rechallengeable Status/Hematological Status of patients to the requesting approved suppliers† of clozapine within 24 hours of receipt of a written request (see 1 INDICATIONS).

The dosage of CLOZARIL® must be adjusted individually. For each patient the lowest effective dose should be used.

† “approved supplier” is a manufacturer who holds a valid Notice of Compliance (NOC) for clozapine.
4.2 Recommended Dose and Dosage Adjustment

Initial Dose
On the first day, CLOZARIL® should be given at a 12.5 mg dose (one-half of a 25 mg tablet) once or twice, followed by one or two 25 mg tablets on the second day. If well tolerated, the dosage may be increased in daily increments of 25 mg to 50 mg, achieving a target dose of 300-450 mg/day by the end of two weeks. Subsequent dosage increases should be made no more than once or twice weekly, in increments not to exceed 100 mg. Cautious titration and a divided dosage schedule are necessary to minimize the risks of hypotension, seizure and sedation (see also 9 DRUG INTERACTIONS).

Switching from Previous Neuroleptics
When CLOZARIL® therapy is initiated in a patient undergoing oral neuroleptic therapy, it is generally recommended that the other neuroleptic should first be discontinued by tapering the dosage downwards. Once the neuroleptic is completely discontinued for at least 24 hours, CLOZARIL® treatment can be started as described above. It is generally recommended that CLOZARIL® should not be used in combination with other neuroleptics.

Therapeutic Dose Range
In most patients, antipsychotic efficacy can be expected within the therapeutic range of 300-600 mg/day in divided doses. The total daily dose may be divided unevenly, with the larger portion at bedtime.

Since improvement may be gradual, continued therapeutic response can be expected beyond the first month of treatment.

Maximum Dose
Occasionally, patients may require doses higher than 600 mg/day to obtain an acceptable therapeutic response. Because of the possibility of increased adverse reactions (particularly seizures) at daily doses of 600 mg and higher, the decision to treat in the range of 600-900 mg/day must be taken prudently. Patients must be given adequate time to respond to a given dose level before escalation to a higher dose is contemplated. The maximum dose of 900 mg/day should not be exceeded.

Maintenance Dose
After achieving maximum therapeutic benefit, many patients can be maintained effectively at lower doses. Careful downward titration is recommended to the level of 150-300 mg/day in divided doses. At daily doses not exceeding 200 mg, a single administration in the evening may be appropriate. Patients should be periodically reassessed to determine the continued need for maintenance treatment.

Dosing Considerations in Special Populations
Patients 60 years of age and older: It is recommended that treatment in patients 60 years and older is initiated at a particularly low dose of CLOZARIL® (12.5 mg given once on the first day) with subsequent dose increments restricted to 25 mg/day.

Pediatrics (< 18 years of age): No pediatric studies have been performed. The safety and efficacy of CLOZARIL® in children and adolescents have not been established.
Cardiovascular disorders: Severe cardiovascular disorders are contraindications. CLOZARIL® should be used with caution in patients with known cardiovascular and/or pulmonary disease, particularly in those with cardiac arrhythmias and conduction disturbances, and the recommendation for gradual titration of dose should be carefully observed.

Renal impairment: In patients with mild to moderate renal impairment the initial dose of CLOZARIL® should be 12.5 mg given once on the first day, and dosage increase should be slow and in small increments.

Hepatic impairment: Patients with hepatic impairment should receive CLOZARIL® with caution along with regular monitoring of liver function tests (see 7 WARNINGS AND PRECAUTIONS, Hepatic/Biliary/Pancreatic).

Discontinuation of Therapy
In the event of planned termination of CLOZARIL® therapy, gradual reduction in dose is recommended over a 1 to 2-week period. However, should a patient's medical condition require abrupt discontinuation (e.g., severe leukopenia, cardiovascular toxicity), the patient should be carefully observed for the recurrence of psychotic symptoms and symptoms related to cholinergic rebound such as headache, nausea, vomiting and diarrhea (see 7 WARNINGS AND PRECAUTIONS, General).

Re-Initiation of Treatment in Patients Previously Discontinued
CLOZARIL® therapy must not be resumed in:
- Patients who have been discontinued from treatment due to CLOZARIL® induced neutropenia (ANC <1.5 x 10^9/L, i.e. Non-rechallengeable Status)
- Patients with clozapine-induced myocarditis

When restarting patients who have had even a brief interval off CLOZARIL® i.e., two days or more since the last dose, it is recommended that treatment be re-initiated with 12.5 mg (one half of a 25 mg tablet) once or twice on the first day (see 4 DOSAGE AND ADMINISTRATION for hematological testing conditions). If that dose is well tolerated, it may be feasible to titrate patients back to a therapeutic dose more quickly than is recommended for initial treatment.

Certain additional precautions seem prudent when re-initiating treatment. The mechanisms underlying some of the CLOZARIL®-induced adverse reactions are unknown. It is conceivable that re-exposure of a patient might enhance the risk of an untoward event's occurrence and increase its severity. Such phenomena, for example, occur when immune mediated mechanisms are responsible. Therefore, any patient who has previously experienced respiratory or cardiac arrest with initial dosing but was then able to be successfully titrated to a therapeutic dose, should be re-titrated with extreme caution after even 24 hours of discontinuation.

If therapy is disrupted for more than 3 days, weekly hematological testing should be resumed for an additional 6 weeks (see 7 WARNINGS AND PRECAUTIONS, Severe Neutropenia)

4.4 Administration
For product administration, refer to 4.2 Recommended Dose and Dosage Adjustment. The tablet may be crushed if required.
4.5 Missed Dose

If a dose of CLOZARIL® is missed and remembered within two hours, then it may be taken immediately. Otherwise, the missed dose is skipped and the regular dosing schedule is continued. Double doses should not be taken. If dosing is missed for two days or more, see Re-Initiation of Treatment in Patients Previously Discontinued above.

5 OVERDOSAGE

The signs and symptoms associated with clozapine overdose are: agitation, areflexia, aspiration pneumonia, blurred vision, cardiac arrhythmias, collapse, coma, confusion, convulsions, delirium, drowsiness, dyspnea, extrapyramidal symptoms, hallucinations, heart block, hyperreflexia, hypersalivation, hypotension, mydriasis, tachycardia, thermolability, and respiratory depression or failure.

In cases of acute intentional or accidental clozapine overdosage, for which information on the outcome is available, to date the mortality is about 12%. Most of the fatalities were associated with cardiac failure or pneumonia caused by aspiration and occurred at doses above 2,000 mg. There have been reports of patients recovering from an overdose in excess of 10,000 mg. However, in a few adult individuals, primarily those not previously exposed to clozapine, the ingestion of doses as low as 400 mg led to life-threatening comatose conditions and, in one case, to death. In young children, the intake of 50 mg to 200 mg resulted in strong sedation or coma without being lethal.

Treatment of Overdosage
Establish and maintain an airway; ensure adequate oxygenation and ventilation. Perform gastric lavage and/or the administration of activated charcoal within the first 6 hours after the ingestion of the drug. Activated charcoal, which may be used with sorbitol, may be as or more effective than emesis or lavage, and should be considered in treating overdosage. Cardiac and vital signs monitoring is recommended along with general symptomatic and supportive measures. Surveillance should be continued for several days because of the risk of delayed effects. Avoid epinephrine when treating hypotension, and quinidine and procainamide when treating cardiac arrhythmia.

There are no specific antidotes for CLOZARIL® (clozapine). Forced diuresis, dialysis, hemoperfusion and exchange transfusion are unlikely to be of benefit.

In managing overdose, the physician should consider the possibility of multiple drug involvement.

For management of a suspected drug overdose, contact your regional poison control centre.
### 6 DOSAGE FORMS, STRENGTHS, COMPOSITION AND PACKAGING

**Table 1 - Dosage Forms, Strengths, Composition and Packaging.**

<table>
<thead>
<tr>
<th>Route of Administration</th>
<th>Dosage Form / Strength/Composition</th>
<th>Non-medicinal Ingredients</th>
</tr>
</thead>
<tbody>
<tr>
<td>Oral</td>
<td>CLOZARIL® 25 mg tablets; Each round, pale yellow, uncoated, easy-to-break, scored tablet, debossed “Clozaril” on one side and “25 mg” on the other, contains clozapine 25 mg. Bottle of 100.</td>
<td>Colloidal silicon dioxide, lactose, magnesium stearate, povidone, starch, and talc.</td>
</tr>
<tr>
<td>Oral</td>
<td>CLOZARIL® 50 mg tablets; Each round, pale yellow, uncoated, easy-to-break, scored tablet, debossed “Clozaril” on one side and “50 mg” on the other, contains clozapine 50 mg. Bottle of 100.</td>
<td>Colloidal silicon dioxide, lactose, magnesium stearate, povidone, starch, and talc.</td>
</tr>
<tr>
<td>Oral</td>
<td>CLOZARIL® 100 mg tablets; Each round, pale yellow, uncoated, easy-to-break, scored tablet, debossed “Clozaril” on one side and “100 mg” on the other, contains clozapine 100 mg. Bottles of 100.</td>
<td>Colloidal silicon dioxide, lactose, magnesium stearate, povidone, starch, and talc.</td>
</tr>
<tr>
<td>Oral</td>
<td>CLOZARIL® 200 mg tablets; Each capsule-shaped, pale yellow, uncoated, angle scored tablet, debossed “Clozaril” on one side and “200” angle scored “mg” on the other, contains clozapine 200 mg. Bottle of 100.</td>
<td>Colloidal silicon dioxide, lactose, magnesium stearate, povidone, starch, and talc.</td>
</tr>
</tbody>
</table>

CLOZARIL® is available only through a distribution system that requires weekly, every-two-week or every-four-week hematological testing prior to the delivery of the next period’s supply of medication (see 1 INDICATIONS).
7 WARNINGS AND PRECAUTIONS

Please see 3 SERIOUS WARNINGS AND PRECAUTIONS BOX.

General

Neutropenia: Because of the significant risk of neutropenia, patients must be monitored as defined in the monograph. (See also 7 WARNINGS AND PRECAUTIONS, Hematologic, Severe Neutropenia). To improve and standardize understanding, “neutropenia” replaces the previous terms leukopenia, granulocytopenia, or agranulocytosis.

Fever: During CLOZARIL® therapy, patients may experience transient temperature elevations above 38°C (100.4°F) with the peak incidence within the first three weeks of treatment. This fever is generally benign and self-limiting; however, on occasion there may be an associated increase or decrease in the white blood cell count. Patients should be carefully evaluated to rule out the possibility of an underlying infectious process or the development of blood dyscrasias. In the presence of high fever, the possibility of neuroleptic malignant syndrome must be considered (see 7 WARNINGS AND PRECAUTIONS, Neurologic). If the diagnosis of neuroleptic malignant syndrome is confirmed, CLOZARIL® should be discontinued immediately and appropriate medical measures should be administered. Fever that is otherwise unexplained can accompany myocarditis (see 7 WARNINGS AND PRECAUTIONS, Cardiovascular).

Anticholinergic Activity: CLOZARIL® has potent anticholinergic effects, which may produce undesirable effects throughout the body. Great care should be exercised in using the drug in the presence of prostatic enlargement, narrow-angle glaucoma or paralytic ileus. Probably on account of its anticholinergic properties, CLOZARIL® has been associated with varying degrees of impairment of intestinal peristalsis, ranging from constipation to intestinal obstruction, fecal impaction and paralytic ileus, megacolon and intestinal infarction/ischemia. On rare occasions, these cases have been fatal. Careful monitoring during treatment with Clozaril® to identify early the onset of constipation, followed by effective management of constipation are recommended to prevent complications. Particular care is necessary in patients who are receiving concomitant medications known to cause constipation (especially those with anticholinergic properties such as some antipsychotics, antidepressants and antiparkinsonian treatments), have a history of colonic disease or a history of lower abdominal surgery as these may exacerbate the situation. It is vital that constipation is recognized and actively treated.

Rebound, withdrawal effects: If abrupt discontinuation of CLOZARIL® is necessary (e.g., because of leukopenia), the patient should be carefully observed for the recurrence of psychotic symptoms and symptoms related to cholinergic rebound such as profuse sweating, headache, nausea, vomiting and diarrhea.

Cardiovascular

Cardiotoxicity: IMPORTANT SAFETY INFORMATION REGARDING A CONSTELLATION OF CARDIOVASCULAR EVENTS REPORTED IN PATIENTS TREATED WITH CLOZAPINE:
Analysis of safety databases suggests that the use of clozapine is associated with an increased risk of myocarditis and cardiomyopathy, especially during, but not limited to, the first two months of therapy. Myocarditis has been reported in patients 19 years of age and older, at dosages within the approved dosage range.
Pericarditis, and pericardial effusion have also been reported in association with clozapine use, as have heart failure, myocardial infarction and mitral insufficiency; these reports include
fatalities. Eosinophilia has been co-reported in some cases, which may indicate that the carditis is a hypersensitivity reaction to clozapine; however, it is not known whether eosinophilia is a reliable predictor of carditis. (See also 7 WARNINGS AND PRECAUTIONS, Eosinophilia).

Patients with a family history of heart failure should have a cardiac evaluation prior to commencing treatment; clozapine is contraindicated in patients with severe cardiac disease.

Discontinue CLOZARIL® and obtain an urgent cardiac evaluation upon suspicion of myocarditis or cardiomyopathy, or other significant cardiotoxicity. Generally, patients with a history of clozapine-associated myocarditis or cardiomyopathy should not be rechallenged with CLOZARIL®. Recurrences of myocarditis upon rechallenge with clozapine have been documented. However, if the benefit of CLOZARIL® treatment is judged to outweigh the potential risks of recurrent myocarditis or cardiomyopathy, the clinician may consider rechallenge with CLOZARIL® in consultation with a cardiologist, after a complete cardiac evaluation, and under close monitoring.

Consider the possibility of myocarditis or cardiomyopathy in patients receiving CLOZARIL® who present with chest pain, dyspnea, persistent tachycardia at rest, palpitations, fever that is otherwise unexplained, fatigue, flu-like symptoms, hypotension, other signs or symptoms of heart failure (e.g. chest pain, tachypnea (shortness of breath), or arrhythmias), or electrocardiographic findings (low voltages, ST-T abnormalities, arrhythmias, right axis deviation, and poor R wave progression and/or raised jugular venous pressure). Myocarditis most frequently presents within the first 2 months of clozapine treatment.

Symptoms of cardiomyopathy generally occur later than clozapine-associated myocarditis and usually after 8 weeks of treatment. However, myocarditis and cardiomyopathy can occur at any period during treatment with CLOZARIL®. It is common for nonspecific flu-like symptoms such as malaise, myalgia, pleuritic chest pain, and low-grade fevers to precede more overt signs of heart failure. Typical laboratory findings include elevated troponin I or T, elevated creatinine kinase-MB, peripheral eosinophilia, and elevated C-reactive protein (CRP). Chest x-ray may demonstrate cardiac silhouette enlargement, and cardiac imaging (echocardiogram, radionuclide studies, or cardiac catheterization) may reveal evidence of left ventricular dysfunction. In patients who are diagnosed with cardiomyopathy while taking CLOZARIL® mitral valve incompetence has been reported. These cases reported either mild or moderate mitral regurgitation on two-dimensional echocardiography. In patients with suspected cardiomyopathy, consider a 2D-echo Doppler examination to identify mitral valve incompetence.

Other Adverse Cardiovascular and Respiratory Effects
CLOZARIL® should be used with caution in patients with known cardiovascular and/or pulmonary disease, particularly in those with cardiac arrhythmias and conduction disturbances, and the recommendation for gradual titration of dose should be carefully observed (initial dose should be 12.5 mg given once on the first day, and dosage increase should be slow and in small increments (see 4.2 Recommended Dose and Dosage Adjustment)).

Orthostatic hypotension, with or without syncope, can occur during CLOZARIL® treatment and may represent a continuing risk in some patients. Rarely (approximately 1 case per 3,000 patients in the United States), collapse can be profound and can be accompanied by respiratory and/or cardiac arrest. Orthostatic hypotension is more likely to occur during initial titration in association with rapid dose escalation and may even occur on first dose. In one report, initial doses as low as 12.5 mg were associated with collapse and respiratory arrest. When restarting patients who have had even a brief interval of CLOZARIL®, i.e., 2 days or more since the last
dose, it is recommended that treatment be reinitiated with one-half of a 25 mg tablet (12.5 mg) once or twice daily (see 4.2 Recommended Dose and Dosage Adjustment).

Cases of collapse/ respiratory arrest/ cardiac arrest during initial clozapine treatment occurred in patients administered clozapine by itself and in patients administered clozapine in combination with benzodiazepines or other psychotropic drugs. Although it has not been established that there is an interaction between CLOZARIL® and benzodiazepines or other psychotropics, caution is advised when clozapine is initiated in patients taking a benzodiazepine or any other psychotropic drug.

Tachycardia, which may be sustained, has been observed in approximately 25% of patients taking CLOZARIL® with patients having an average increase in pulse rate of 10 to 15 bpm. The sustained tachycardia is not simply a reflex response to hypotension and is present in all positions monitored. Tachycardia may be due to the anticholinergic effect of CLOZARIL® and its ability to elevate plasma norepinephrine. Either tachycardia or hypotension may pose a serious risk for an individual with compromised cardiovascular function.

A minority of CLOZARIL®-treated patients experience ECG repolarization changes similar to those seen with other antipsychotic drugs, including S-T segment depression and flattening or inversion of T waves. The clinical significance of these changes is unclear. However, in clinical trials with clozapine, several patients experienced significant cardiac events, including ischemic changes, myocardial infarction, arrhythmias, and sudden death. In addition, there have been post-marketing reports of congestive heart failure. Causality assessment was difficult in many of these cases due to serious preexisting cardiac disease and plausible alternative causes. Rare instances of sudden, unexplained death have been reported in psychiatric patients, with or without associated antipsychotic drug treatment, and the relationship of these events to antipsychotic drug use is unknown.

**QT interval prolongation:** As with other antipsychotics, caution is advised in patients with known cardiovascular disease, a family history of QT prolongation, or when CLOZARIL® is prescribed with medicines known to increase the QTc interval.

**Venous Thromboembolism:** Venous thromboembolism (VTE), including fatal pulmonary embolism, has been reported with antipsychotic drugs including CLOZARIL®, in case reports and/or observational studies. When prescribing CLOZARIL® all possible risk factors for VTE should be identified before and during treatment with CLOZARIL® and preventative measures undertaken.

Since CLOZARIL® may cause sedation and weight gain, thereby increasing the risk of thromboembolism, immobilization of patients should be avoided.

**Driving and Operating Machinery**

Due to the risk of convulsions during CLOZARIL® treatment, activities where a sudden loss of consciousness could occur should be avoided (e.g., driving, using machines, swimming, climbing).

Because of the potential for initial sedation, CLOZARIL® may impair mental and/or physical abilities especially during the first few days of therapy. The recommendation for gradual dose escalation should be carefully adhered to and patients should be cautioned about activities requiring alertness (e.g., driving, operating machinery, swimming, climbing, etc.) (see 4.2 Recommended Dose and Dosage Adjustment).
Endocrine and Metabolism

**Metabolic Changes:** Atypical antipsychotic drugs, including CLOZARIL®, have been associated with metabolic changes that may increase cardiovascular/cerebrovascular risk. These metabolic changes may include hyperglycemia, dyslipidemia, and body weight gain. While atypical antipsychotic drugs may produce some metabolic changes, each drug in the class has its own specific risk profile.

**Hyperglycemia:** On rare occasions, severe hyperglycemia, sometimes leading to ketoacidosis/hyperosmolar coma including some fatal cases, has been reported during CLOZARIL® treatment in patients with no prior history of hyperglycemia. While a causal relationship to clozapine use has not been definitely established, glucose levels returned to normal in most patients after discontinuation of CLOZARIL® and rechallenge produced a recurrence of hyperglycemia in a few cases. The effect of clozapine on glucose metabolism in patients with diabetes mellitus has not been studied. Impaired glucose tolerance, severe hyperglycemia, ketoacidosis and hyperosmolar coma have been reported in patients with no prior history of hyperglycaemia. Patients should have baseline and periodic monitoring of blood glucose and body weight. In patient receiving CLOZARIL® who developed symptom of hyperglycaemia, such as polydipsia, polyuria, polyphagia or weakness discontinuation should be considered.

There is a risk of altering the metabolic balance resulting in slight impairment of glucose homeostasis and a possibility of unmasking a pre-diabetic condition or aggravating pre-existing diabetes.

Assessment of the relationship between atypical antipsychotic use and glucose abnormalities is complicated by the possibility of an increased background risk of diabetes mellitus in patients with schizophrenia and the increasing incidence of diabetes mellitus in the general population. Given these confounders, the relationship between atypical antipsychotic use and hyperglycemia-related adverse events is not completely understood. However, epidemiological studies suggest an increased risk of treatment-emergent hyperglycemia-related adverse events in patients treated with the atypical antipsychotics. Precise risk estimates for hyperglycemia-related adverse events in patients treated with atypical antipsychotics are not available.

Any patient treated with atypical antipsychotics should be monitored for symptoms of hyperglycemia including polydipsia, polyuria, polyphagia, and weakness. Patients who develop symptoms of hyperglycemia during treatment with atypical antipsychotics should undergo fasting blood glucose testing. In some cases, hyperglycemia has resolved when the atypical antipsychotic was discontinued; however, some patients required continuation of anti-diabetic treatment despite discontinuation of the suspect drug. Patients with risk factors for diabetes mellitus (e.g., obesity, family history of diabetes) who are starting treatment with atypical antipsychotics should undergo fasting blood glucose testing at the beginning of treatment and periodically during treatment. Patients with an established diagnosis of diabetes mellitus who are started on atypical antipsychotics should be monitored regularly for worsening of glucose control.

**Dyslipidemia:** Undesirable alterations in lipids have been observed in patients treated with atypical antipsychotics, including CLOZARIL®. Clinical monitoring, including baseline and periodic follow-up lipid evaluations in patients using clozapine, is recommended.
**Weight Gain:** Weight gain has been observed with atypical antipsychotic use, including CLOZARIL®. Clinical monitoring of weight is recommended.

**Genitourinary**

Very rare cases of priapism have been reported with CLOZARIL®. This adverse reaction, as with other psychotropic drugs, did not appear to be dose-dependent and did not correlate with the duration of treatment.

**Hematologic**

**Severe Neutropenia:** Because of the significant risk of neutropenia, a potentially life-threatening adverse event (see below), CLOZARIL® should be reserved for use in the treatment of schizophrenic patients who fail to show an acceptable response to adequate courses of conventional antipsychotic drug treatment, either because of insufficient effectiveness or the inability to achieve an effective dose due to intolerable adverse effects.

Fatalities occurring in association with clozapine-induced neutropenia have generally resulted from infections due to compromised immune system responses. Therefore, patients should be advised to report immediately the appearance of lethargy, weakness, fever, sore throat, flu-like complaints or any other signs of infection.

CLOZARIL® is available only through a distribution system (CSAN) that requires weekly, every-two-week, or every-four-week hematological testing prior to the dispensing of the next period's supply of CLOZARIL® (see INDICATIONS).

Patients must have a normal absolute neutrophil count (ANC), i.e., ≥2.0 x 10⁹/L; ≥1.0 x 10⁹/L in BEN patients) count prior to starting clozapine therapy. The ANC is usually available as a component of the complete blood count (CBC), including differential, and is more relevant to drug-induced neutropenia than is the white blood cell (WBC). Subsequently, an ANC must be carried out at least weekly for the first 26 weeks of treatment with clozapine. Thereafter, if acceptable ANC 2.0 x 10⁹/L have been maintained during the first 26 weeks of continuous therapy, the ANC can be performed at least at two-week intervals for the next 26 weeks. Thereafter, if acceptable ANCs (ANC ≥2.0 x 10⁹/L) have been maintained during the second 26 weeks of continuous therapy, the ANC can be performed at least every four weeks throughout treatment.

**ANC Count Guidelines**

CLOZARIL® treatment should be initiated and carried out according to the following guidelines:

- Treatment should not be initiated if the ANC count is less than 2.0 x 10⁹/L (<1.0 x 10⁹/L for patients with BEN), or if the patient has a history of a myeloproliferative disorder, or toxic or idiosyncratic neutropenia (with the exception of agranulocytosis from previous chemotherapy).

- Independently of the frequency of their blood monitoring regimen (weekly, at two-week, or at four-week intervals), patients should be evaluated immediately, and ANC checked at least **twice weekly** if after the initiation of treatment, ANC falls according to the Table below.
Table 2 - ANC Count Guidelines

<table>
<thead>
<tr>
<th>ANC (/L)</th>
<th>Non-BEN patients</th>
<th>BEN patients</th>
<th>Action Required</th>
</tr>
</thead>
<tbody>
<tr>
<td>≥ 2.0 x 10^9</td>
<td>≥ 1.0 x 10^9</td>
<td>Continue CLOZARIL® treatment</td>
<td></td>
</tr>
<tr>
<td>≥ 1.5 x 10^9 and &lt; 2.0 x 10^9</td>
<td>≥ 0.5 x10^9 and &lt; 1.0 x 10^9</td>
<td>Continue CLOZARIL® treatment, sample blood twice weekly until counts stabilise or increase</td>
<td></td>
</tr>
<tr>
<td>&lt; 1.5 x 10^9</td>
<td>&lt; 0.5 x 10^9</td>
<td>Immediately stop CLOZARIL® treatment, sample blood daily until haematological abnormality is resolved, monitor for infection. Do not re-expose the patient. (&quot;Non-rechallengeable Status&quot;)</td>
<td></td>
</tr>
</tbody>
</table>

- In the event of a fall in ANC to below 1.5 x 10^9/L, CLOZARIL® therapy must be immediately withheld and the patient closely monitored. WBC counts and differential blood counts should then be performed daily, and patients should be carefully monitored for flu-like symptoms or other symptoms suggestive of infection. The patient is to be assigned “Non-rechallengeable” status upon confirmation of fall in ANC. CLOZARIL® therapy must not be resumed. Confirmation of the haematological values is recommended by performing two blood counts on two consecutive days; however, CLOZARIL® should be discontinued after the first blood count. Particular attention should be paid to any flu-like complaints or other symptoms which might suggest infection. If the patient should develop a further fall in the WBC count to below 1.0 x 10^9/L, or a decrease in ANC to below 0.5 x 10^9/L, it is recommended that patients be placed in protective isolation with close observation and be watched for signs of infection by their physician. Should evidence of infection develop, the appropriate cultures should be performed, and an appropriate antibiotic regimen instituted.

- Benign ethnic neutropenia (BEN) is a condition observed in certain ethnic groups whose average ANC values are lower than “standard” laboratory ranges for neutrophils. It is most commonly observed in individuals of African descent (approximate prevalence of 25-50%), some Middle Eastern ethnic groups, and in other non-Caucasian ethnic groups with darker skin. BEN is more common in men. Patients with BEN have normal hematopoietic stem cell number and myeloid maturation, are healthy, and do not suffer from repeated or severe infections. They are not at increased risk for developing CLOZARIL® induced neutropenia. Additional evaluation may be needed to determine if baseline neutropenia is due to BEN. Consider hematology consultation before initiating or during CLOZARIL® treatment as necessary. Patients with BEN require a different ANC algorithm for CLOZARIL® management due to their lower baseline ANC levels (see Table 2 above)
Monitoring Schedule Guideline

The change from a weekly to a "once every two weeks", or from a “once every two weeks” to a “once every four weeks” schedule should be evaluated on an individual patient basis after 26 and 52 weeks of treatment, respectively. This decision should be made based upon the hematological profile of the patient during the first 26 or 52 weeks of treatment (as appropriate), as well as on the clinical judgement of the treating physician, and if they deem it appropriate, a consulting hematologist, and on the patient's willingness to pursue a given frequency of blood monitoring. In turn, the clinical evaluation should take into consideration possible factors that would place the patient in a higher risk group.

Monitoring must continue for as long as the patient is on the drug. Monitoring frequency does not have to be modified if therapy is interrupted for 3 days or less. However, weekly hematological testing should be resumed for at least an additional 6 weeks if therapy is disrupted for more than 3 days (see Table 3). Furthermore, monitoring should occur at least weekly following discontinuation of clozapine therapy until ANC is $\geq 2.0 \times 10^9$ ($\geq 1.0 \times 10^9$ for BEN patients), irrespective of the cause of discontinuation.

Table 3 - Resuming Monitoring Frequency after Interruption in Therapy

<table>
<thead>
<tr>
<th>Duration of Treatment prior to Interruption</th>
<th>≤ 6 months</th>
<th>6 – 12 months</th>
<th>&gt; 12 months</th>
</tr>
</thead>
<tbody>
<tr>
<td>Length of Interruption</td>
<td>3 days – 4 weeks</td>
<td>&gt; 4 weeks</td>
<td>&gt; 4 weeks</td>
</tr>
<tr>
<td>Monitoring Frequency after Therapy resumed</td>
<td>Weekly for 6 weeks</td>
<td>Weekly for 6 weeks, then every 2 weeks for 6 months</td>
<td>Weekly for 6 months, then every 2 weeks for 6 months</td>
</tr>
</tbody>
</table>

The cumulative incidence of neutropenia with CLOZARIL® use is 2.6%. This cumulative incidence can be further divided into moderate neutropenia (1.24%), severe neutropenia (0.62%) and agranulocytosis (0.76%).

Rare fatal cases of clozapine-induced neutropenia have been reported in association with CLOZARIL®. However, more than half of these deaths occurred before 1977, prior to the recognition of the risk of neutropenia and the need for routine blood monitoring.

The development of neutropenia and agranulocytosis does not appear to be dependent on the duration of treatment. Recent Canadian data indicate that approximately 51% of the cases of neutropenia have occurred during the first 26 weeks of therapy, and 41% occurred after ≥52 weeks of treatment, underscoring the need for continued monitoring. Experience in Canada (38,996 patients ever exposed to April 2019) reveals that the mean age of patients treated with clozapine is 39.3 years while the mean age of patients experiencing a hematological event is 44 years and 47 years for those experiencing agranulocytosis.
Patients who have shown hematopoietic reactions to other medications may also be more likely to demonstrate such reactions with clozapine.

Neutropenia associated with other antipsychotic drugs has been reported to occur with a greater frequency in patients who are cachectic or have a serious underlying medical illness.

**Eosinophilia:** In the event of eosinophilia, it is recommended to discontinue CLOZARIL® if the eosinophil count rises above 3.0 x 10^9/L, and to re-start therapy only after the eosinophil count has fallen below 1.0 x 10^9/L. Eosinophilia has been co-reported in some cases of myocarditis and thus such cardiovascular adverse events associated with clozapine use may represent hypersensitivity reactions to clozapine. See also 7 WARNINGS AND PRECAUTIONS, Skin, Severe Cutaneous Adverse Reactions (SCARs)).

Patients with both eosinophilia and clozapine-induced myocarditis should not be re-exposed to clozapine.

**Thrombocytopenia:** In the event of thrombocytopenia, it is recommended to discontinue CLOZARIL® therapy if the platelet count falls below 50.0 x 10^9/L.

**Hepatic/Biliary/Pancreatic**

**Hepatotoxicity:** Severe, life threatening, and in some cases fatal hepatotoxicity including hepatic failure, hepatic necrosis, and hepatitis have been reported in post marketing studies in patients treated with clozapine. Monitor for the appearance of signs and symptoms of hepatotoxicity such as fatigue, malaise, anorexia, nausea, jaundice, bilirubinemia, coagulopathy, and hepatic encephalopathy. Perform serum tests for liver injury and consider permanently discontinuing treatment, if hepatitis or transaminase elevations combined with other systemic symptoms are due to clozapine.

**Hepatic impairment:** Patients with stable pre-existing liver disorders may receive CLOZARIL® but need regular liver function tests. In patients in whom, during CLOZARIL® treatment, symptoms of possible liver dysfunction such as nausea, vomiting and/or anorexia develop, liver function tests should be performed immediately. If the elevation of these values is clinically relevant or if symptoms of jaundice occur, treatment with CLOZARIL® must be discontinued. It may be resumed (see 4.2 Recommended Dose and Dosage Adjustment, Re-Initiation of Treatment in Patients Previously Discontinued) only when the liver function tests have returned to normal values. In such cases, liver function should be closely monitored after the re-introduction of the drug.

**Neurologic**

**Seizures:** CLOZARIL® may lower seizure threshold. Caution should be used in administering CLOZARIL® to patients having a history of seizures or other predisposing factors.

Seizures have been estimated to occur in association with CLOZARIL® use at a cumulative incidence at one year of approximately 5%, based on the occurrence of one or more seizures in the patients exposed to CLOZARIL® during clinical trials in the United States. Dose appears to be an important predictor of seizure. At doses below 300 mg/day, seizure risk is comparable to that of other antipsychotic drugs (about 1-2%). At higher doses, seizure risk rises accordingly, reaching 5% at doses of 600 to 900 mg/day. Because of the risk of seizure associated with
CLOZARIL® use, patients should be advised not to engage in any activity where sudden loss of consciousness could cause serious risk to themselves or others (e.g., driving, operating machinery, swimming, climbing, etc.)

**Falls:** CLOZARIL®, like other antipsychotics, may cause somnolence, postural hypotension, motor and sensory instability, which may lead to falls and, consequently, fractures or other injuries. For patients with diseases, conditions, or medications that could exacerbate these effects, complete fall risk assessments when initiating antipsychotic treatment and recurrently for patients on long-term antipsychotic therapy.

**Neuroleptic Malignant Syndrome:** A potentially fatal symptom complex sometimes referred to as neuroleptic malignant syndrome (NMS) has been reported in association with antipsychotic drugs. Cases of NMS have been reported in patients treated with clozapine, most of which have included the concomitant use of lithium or other CNS-active agents.

Clinical manifestations of NMS are hyperpyrexia, muscle rigidity, altered mental status (including catatonic signs) and evidence of autonomic instability (irregular pulse or blood pressure, tachycardia, diaphoresis, and cardiac dysrhythmias). Additional signs may include elevated creatine phosphokinase, myoglobinuria (rhabdomyolysis), and acute renal failure. The diagnostic evaluation of patients with this syndrome is complicated. In arriving at a diagnosis, it is important to identify cases where the clinical presentation includes both serious medical illness (e.g., pneumonia, systemic infection, etc.) and untreated or inadequately treated extrapyramidal signs and symptoms (EPS). Other important considerations in the differential diagnosis include central anticholinergic toxicity, heat stroke, drug fever and primary central nervous system (CNS) pathology.

The management of NMS should include: (1) immediate discontinuation of antipsychotic drugs and other drugs not essential to concurrent therapy; (2) intensive symptomatic treatment and medical monitoring; and (3) treatment of any concomitant serious medical problems for which specific treatments are available. There is no general agreement about specific pharmacological treatment regimens for uncomplicated NMS.

If a patient requires antipsychotic drug treatment after recovery from NMS, the potential reintroduction of drug therapy should be carefully considered. The patient should be carefully monitored, since recurrences of NMS have been reported.

**Tardive Dyskinesia:** A syndrome consisting of potentially irreversible, involuntary, dyskinetic movements may develop in patients treated with conventional antipsychotic drugs. Although the prevalence of tardive dyskinesia with conventional antipsychotics appears to be highest among the elderly, especially elderly women, it is impossible to rely upon prevalence estimates to predict, at the beginning of treatment, which patients are likely to develop the syndrome.

Both the risk of developing tardive dyskinesia and the likelihood that it will become irreversible are believed to increase as the duration of treatment and the total cumulative dose of antipsychotic drugs administered to the patient increase. However, the syndrome can develop, although much less commonly, after relatively brief treatment periods at low doses. There is no known treatment for established cases of tardive dyskinesia, although the syndrome may remit, partially or completely, if antipsychotic drug treatment is withdrawn. Antipsychotic drug treatment itself, however, may suppress (or partially suppress) the signs and symptoms of
tardive dyskinesia and thereby may possibly mask the underlying process. The effect that symptom suppression has upon the long-term course of the syndrome is unknown.

There are several reasons for predicting that CLOZARIL® may be different from other antipsychotic drugs in its potential for inducing tardive dyskinesia. These include the preclinical finding that it has a relatively weak dopamine receptor blocking effect and the clinical finding that it is associated with a low incidence of extrapyramidal symptoms. Very rarely tardive dyskinesia has been reported in patients on clozapine who had been previously treated with other antipsychotic agents, so that a causal relationship cannot be established. Nevertheless, it cannot be concluded, without more extended experience, that CLOZARIL® will not induce this syndrome.

Given this consideration, CLOZARIL® should be prescribed in a manner that is most likely to minimize the risk of the occurrence of tardive dyskinesia. As with any antipsychotic drug, chronic CLOZARIL® use should be reserved for patients who appear to be obtaining substantial benefit from the drug. In such patients, the smallest dose and the shortest duration of treatment should be sought. The need for continued treatment should be reassessed periodically.

Patients in whom tardive dyskinesia developed with other neuroleptics have improved on clozapine.

If signs and symptoms of tardive dyskinesia appear in a patient on CLOZARIL®, drug discontinuation should be considered. However, some patients may require treatment with CLOZARIL® despite the presence of the syndrome.

Renal

**Renal impairment:** In patients suffering from mild to moderate renal impairment, an initial dose of 12.5 mg/day (half a 25 mg tablet) is recommended (see 4.2 Recommended Dose and Dosing Adjustment, Dosing Considerations in Special Populations).

Skin

**Severe Cutaneous Adverse Reactions (SCARs):** Severe cutaneous adverse reactions (SCARs), including Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), drug reaction with eosinophilia and systemic symptoms (DRESS), and acute generalized exanthematous pustulosis (AGEP) are potentially life-threatening adverse drug reactions that have been reported with atypical antipsychotic exposure (see 8.5 Post-Market Adverse Reactions). SCARs commonly present as a combination of the following symptoms: extensive cutaneous rash or exfoliative dermatitis, fever, lymphadenopathy and possible eosinophilia (see 7 WARNINGS AND PRECAUTIONS, Hematologic). Discontinue CLOZARIL® if severe cutaneous adverse reactions occur.

Post market cases of DRESS have been reported in association with clozapine.

7.1 Special Populations

7.1.1 Pregnant Women

Reproduction studies, performed in rats and rabbits at doses of approximately 2 to 4 times the human dose, have revealed no evidence of impaired fertility or harm to the fetus due to
clozapine. However, there have not been any adequate and well-controlled studies in pregnant women. Because animal reproduction studies are not always predictive of human response and in view of the desirability of keeping the administration of all drugs to a minimum during pregnancy, CLOZARIL® should be used only if the benefits clearly outweigh the risks.

**Non-Teratogenic Effects:** Neonates exposed to antipsychotic drugs, during the third trimester of pregnancy are at risk for extrapyramidal and/or withdrawal symptoms following delivery. There have been reports of agitation, hypertonia, hypotonia, tremor, somnolence, respiratory distress and feeding disorder in these neonates. These complications have varied in severity; while in some cases symptoms have been self-limited, in other cases neonates have required intensive care unit support and prolonged hospitalization.

**Women of Childbearing Potential and Contraceptive Measures:** Some female patients treated with antipsychotics other than CLOZARIL® may become amenorrheic. A return to normal menstruation may occur as a result of switching from other antipsychotics to CLOZARIL®. Adequate contraceptive measures must therefore be ensured in women of childbearing potential.

**7.1.2 Breast-feeding**

Animal studies suggest that clozapine may be excreted in breast milk and has an effect in the suckling offspring. Therefore, women receiving CLOZARIL® should not breast-feed.

**7.1.3 Pediatrics**

**Pediatrics (<18 years of age):** No pediatric studies have been performed. Safety and efficacy of CLOZARIL® in children and adolescents below age 18 have not been established and its use is not recommended.

Weight gain has been observed with atypical antipsychotic use in pediatric and adolescent patient populations. Independent of any drug-specific effects, weight gain can be associated with adverse changes in other metabolic parameters (e.g., glucose and lipid metabolism).

Abnormal childhood weight and metabolic status can have adverse effects on cardiovascular outcomes in adulthood. Weight gain and adverse effects on other metabolic parameters associated with atypical antipsychotics can be more frequent or more severe in pediatric and adolescent patients than in the adult patients.

The long-term safety, including cardiometabolic effects and effects on growth, maturation and behavioral development in patients under 18 years of age has not been systematically evaluated.

**7.1.4 Geriatrics**

**Patients aged 60 years and older:** Orthostatic hypotension can occur with CLOZARIL® treatment and there have been rare reports of tachycardia, which may be sustained, in patients taking clozapine. Patients aged 60 years and older, particularly those with compromised cardiovascular function, may be more susceptible to these effects.

Patients aged 60 years and older may also be particularly susceptible to the anticholinergic effects of CLOZARIL®, such as urinary retention and constipation.
Use in Patients aged 60 years and older with Dementia

Overall Mortality
Elderly patients with dementia treated with atypical antipsychotic drugs are at an increased risk of death compared to placebo. Analyses of thirteen placebo-controlled trials with various atypical antipsychotics (modal duration of 10 weeks) in these patients showed a mean 1.6-fold increase in the death rate in the drug-treated patients. Although the causes of death were varied, most of the deaths appeared to be either cardiovascular (e.g., heart failure, sudden death) or infectious (e.g., pneumonia) in nature. CLOZARIL® (clozapine) has not been studied in elderly patients with dementia and therefore no such data were included in this analysis.

Observational studies suggest that, similar to atypical antipsychotic drugs, treatment with conventional antipsychotic drugs may increase mortality. The extent to which the findings of increased mortality in observational studies may be attributed to the antipsychotic drug as opposed to some characteristic(s) of the patients is not clear.

In the published literature, risk factors that may predispose this patient population to increased risk of death when treated with antipsychotics include sedation, the presence of cardiac conditions (e.g., cardiac arrhythmias) or pulmonary conditions (e.g., pneumonia, with or without aspiration).

CLOZARIL® is not indicated for the treatment of elderly patients with dementia

Aspiration Pneumonia
Esophageal dysmotility and aspiration have been associated with antipsychotic drug use. Aspiration pneumonia is a common cause of morbidity and mortality in elderly patients, in particular those with advanced Alzheimer's dementia. CLOZARIL® and other antipsychotic drugs should be used cautiously in patients at risk for aspiration pneumonia.

Cerebrovascular Adverse Events (CVAEs), Including Stroke, in Elderly Patients with Dementia:
In placebo-controlled trials with some atypical antipsychotics, there was a higher incidence of cerebrovascular adverse events (cerebrovascular accidents and transient ischemic attacks) including fatalities compared to placebo-treated subjects. There are insufficient data with clozapine to know if there is an increased risk of cerebrovascular events associated with clozapine. CLOZARIL is not indicated for the treatment of patients with dementia-related psychosis (see also 3 SERIOUS WARNINGS AND PRECAUTIONS BOX).

8 ADVERSE REACTIONS

8.1 Adverse Reaction Overview
The most serious adverse reactions experienced with CLOZARIL® (clozapine) are neutropenia, seizure, cardiovascular effects and fever (see 7 WARNINGS AND PRECAUTIONS, Hematologic). The most common side effects are drowsiness/sedation, dizziness, hypersalivation, tachycardia, and constipation.

Adverse Events Leading to Discontinuation
Of 1080 patients who received clozapine in premarketing clinical trials, 16% discontinued treatment due to an adverse event, including both those that could be reasonably attributed to
clozapine treatment and those that might more appropriately be considered intercurrent illness. The more common events considered to be causes of discontinuation included: CNS (psychotic disorder), primarily drowsiness/sedation, somnolence, seizures, dizziness (excluding vertigo)/syncope; cardiovascular, primarily tachycardia, hypotension and ECG changes; gastrointestinal, primarily nausea/vomiting; hematologic, primarily neutropenia and fever. None of the events enumerated accounts for more than 1.7% of all discontinuations attributed to adverse clinical event.

**Most Frequent Adverse Events**

Adverse events observed in association with the use of clozapine in clinical trials at an incidence of greater than 5% were: central nervous system complaints, including drowsiness/sedation, dizziness/vertigo, headache and tremor; autonomic nervous system complaints, including salivation, sweating, dry mouth and visual disturbances; cardiovascular findings, including tachycardia, hypotension and syncope; and gastrointestinal complaints, including constipation and nausea; and fever. Complaints of drowsiness/sedation tend to subside with continued therapy or dose reduction. Salivation may be profuse, especially during sleep, but may be diminished with dose reduction.

**8.2 Clinical Trial Adverse Reactions**

The following table enumerates adverse events that occurred at a frequency of 1% or greater among clozapine patients who participated in clinical trials. These rates are not adjusted for duration of exposure.

**Table 4 - Treatment-Emergent Adverse Experience Incidence Among Patients Taking Clozapine in Clinical Trials**

<table>
<thead>
<tr>
<th>Body System Adverse Eventa</th>
<th>% Patients (N=842)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Nervous System disorders</strong></td>
<td></td>
</tr>
<tr>
<td>Drowsiness/Sedation</td>
<td>39</td>
</tr>
<tr>
<td>Dizziness/Vertigo</td>
<td>19</td>
</tr>
<tr>
<td>Headache</td>
<td>7</td>
</tr>
<tr>
<td>Tremor</td>
<td>6</td>
</tr>
<tr>
<td>Disturbed sleep/Nightmares</td>
<td>4</td>
</tr>
<tr>
<td>Hypokinesia/Akinesia</td>
<td>4</td>
</tr>
<tr>
<td>Seizures (convulsions)</td>
<td>3b</td>
</tr>
<tr>
<td>Rigidity</td>
<td>3</td>
</tr>
<tr>
<td>Akathisia</td>
<td>3</td>
</tr>
<tr>
<td>Confusion</td>
<td>3</td>
</tr>
<tr>
<td>Insomnia</td>
<td>2</td>
</tr>
<tr>
<td>Hyperkinesia</td>
<td>1</td>
</tr>
<tr>
<td>Weakness</td>
<td>1</td>
</tr>
<tr>
<td>Lethargy</td>
<td>1</td>
</tr>
<tr>
<td>Ataxia</td>
<td>1</td>
</tr>
<tr>
<td>Slurred speech</td>
<td>1</td>
</tr>
<tr>
<td>Depression</td>
<td>1</td>
</tr>
<tr>
<td>Epileptiform movements/Myoclonic jerks</td>
<td>1</td>
</tr>
<tr>
<td>Anxiety</td>
<td>1</td>
</tr>
<tr>
<td><strong>Psychiatric disorders</strong></td>
<td></td>
</tr>
<tr>
<td>Agitation</td>
<td>4</td>
</tr>
<tr>
<td>Restlessness</td>
<td>4</td>
</tr>
<tr>
<td><strong>Cardiac disorders</strong></td>
<td></td>
</tr>
<tr>
<td>Body System</td>
<td>Adverse Event</td>
</tr>
<tr>
<td>------------------------------</td>
<td>----------------------------------------</td>
</tr>
<tr>
<td>Vascular disorders</td>
<td>Tachycardia</td>
</tr>
<tr>
<td></td>
<td>Chest pain/Angina</td>
</tr>
<tr>
<td></td>
<td>ECG changes/Cardiac abnormality</td>
</tr>
<tr>
<td>Gastrointestinal disorders</td>
<td>Syncope</td>
</tr>
<tr>
<td></td>
<td>Hypotension</td>
</tr>
<tr>
<td></td>
<td>Hypertension</td>
</tr>
<tr>
<td></td>
<td>Abdominal discomfort/Heartburn</td>
</tr>
<tr>
<td></td>
<td>Nausea/Vomiting</td>
</tr>
<tr>
<td></td>
<td>Vomiting</td>
</tr>
<tr>
<td></td>
<td>Dry mouth</td>
</tr>
<tr>
<td></td>
<td>Diarrhea</td>
</tr>
<tr>
<td></td>
<td>Anorexia</td>
</tr>
<tr>
<td>Hepatobiliary disorders</td>
<td>Liver test abnormality</td>
</tr>
<tr>
<td>Renal and urinary disorders</td>
<td>Urinary abnormalities</td>
</tr>
<tr>
<td></td>
<td>Urinary incontinence</td>
</tr>
<tr>
<td></td>
<td>Urinary urgency/frequency</td>
</tr>
<tr>
<td></td>
<td>Urinary retention</td>
</tr>
<tr>
<td>Reproductive system disorders</td>
<td>Abnormal ejaculation</td>
</tr>
<tr>
<td>Autonomic Nervous System</td>
<td>Salivation</td>
</tr>
<tr>
<td></td>
<td>Sweating</td>
</tr>
<tr>
<td></td>
<td>Visual disturbances</td>
</tr>
<tr>
<td>Skin and subcutaneous tissue disorders</td>
<td>Rash</td>
</tr>
<tr>
<td></td>
<td>Musculoskeletal</td>
</tr>
<tr>
<td></td>
<td>Muscle weakness</td>
</tr>
<tr>
<td></td>
<td>Pain (back, neck, legs)</td>
</tr>
<tr>
<td></td>
<td>Muscle spasm</td>
</tr>
<tr>
<td></td>
<td>Muscle pain, ache</td>
</tr>
<tr>
<td>Respiratory disorders</td>
<td>Throat discomfort</td>
</tr>
<tr>
<td></td>
<td>Dyspnea, shortness of breath</td>
</tr>
<tr>
<td></td>
<td>Nasal congestion</td>
</tr>
<tr>
<td>Blood and lymphatic disorders</td>
<td>Leukopenia/Decreased WBC/Neutropenia</td>
</tr>
<tr>
<td></td>
<td>Agranulocytosis</td>
</tr>
<tr>
<td></td>
<td>Eosinophilia</td>
</tr>
<tr>
<td>Metabolism and nutrition disorders</td>
<td>Weight gain</td>
</tr>
<tr>
<td>Miscellaneous</td>
<td>Fever</td>
</tr>
<tr>
<td></td>
<td>Fatigue</td>
</tr>
<tr>
<td></td>
<td>Tongue numb/sore</td>
</tr>
</tbody>
</table>

<sup>a</sup> Events reported by at least 1% of clozapine patients are included.

<sup>b</sup> Rate based on population of approximately 1700 exposed during premarket clinical evaluation of clozapine.
Adverse Events Observed During the InterSePT Study
Adverse events reported during the InterSePT study were consistent with the known safety profiles for clozapine and olanzapine. The ten most frequently reported adverse events in the CLOZARIL® treatment group were: salivary hypersecretion, somnolence, weight increase, anxiety, depression, dizziness (excluding vertigo), psychotic disorder, suicidal ideation, constipation, and insomnia.

8.2.1 Clinical Trial Adverse Reactions (Pediatrics)
No pediatric studies have been performed.

8.3 Less Common Clinical Trial Adverse Reactions
Other Adverse Events Observed during Clinical Trials
This section reports additional, less frequent adverse events which occurred among the patients taking clozapine in clinical trials. Various adverse events were reported as part of the total experience in these clinical studies; a causal relationship to clozapine treatment cannot be determined in the absence of appropriate controls in some of the studies. The table above enumerates adverse events that occurred at a frequency of at least 1% of patients treated with clozapine. The list below includes all additional adverse experiences reported as being temporally associated with the use of the drug which occurred at a frequency less than 1%, enumerated in alphabetical order by organ system.

**Autonomic Nervous System**: dry throat, hot flashes, mydriasis, numbness, polydyspia.

**Blood and lymphatic system**: anemia and leukocytosis.

**Cardiac**: arrhythmias, bradycardia, cyanosis, edema, ischemic changes, myocardial infarction, nosebleed, palpitations, phlebitis/thrombophlebitis, premature ventricular contraction, sudden death.

**Eye**: bloodshot eyes, eyelid disorder, nystagmus.

**Gastrointestinal**: abdominal distension, abnormal stools, bitter taste, eructation, gastric ulcer, gastroenteritis, hematemesis, nervous stomach, rectal bleeding

**General**: appetite increase, chills/chills with fever, ear disorder, hypothermia, malaise,

**Musculoskeletal and connective tissue**: joint pain, twitching.

**Nervous System**: amnesia, amnesia/memory loss, delusions/hallucinations, irritability, histrionic movements, involuntary movement, libido increase or decrease, loss of speech, paranoia, Parkinsonism, poor coordination, tics, restless legs syndrome, shakiness.

**Psychiatric**: dysarthria, dysphemia (stuttering).

**Reproductive system**: breast pain/discomfort, dysmenorrhea, impotence, and vaginal itch/infection.
Respiratory: bronchitis, coughing, hyperventilation, laryngitis, pneumonia/pneumonia-like symptoms, rhinorrhea, sneezing, wheezing.

Skin and subcutaneous tissue: bruise, dermatitis, eczema, erythema, pallor, petechiae, pruritus, urticaria.

8.4 Abnormal Laboratory Findings: Hematologic, Clinical Chemistry and Other Quantitative Data

Not applicable.

8.5 Post-Market Adverse Reactions

Post-marketing experience has shown an adverse experience profile similar to that presented above. In post-marketing experience, cases of hepatic, cholestatic or mixed liver injury, hepatic failure, including fatalities, have been reported with the use of clozapine.

Atypical antipsychotic drugs, including clozapine, have been associated with cases of sleep apnea, with or without concomitant weight gain. In patients who have a history of or are at risk for sleep apnea, clozapine should be prescribed with caution.

Sleep walking (SW) and sleep-related eating disorder (SRED) have been associated with the use of atypical antipsychotics, including cases reported with clozapine.

Voluntary reports of adverse events temporally associated with clozapine not mentioned above that have been received since market introduction and that may have no causal relationship with the drug include the following, listed in alphabetical order within system organ class:

**Blood and lymphatic system:** deep vein thrombosis, elevated hemoglobin, ESR increased, pulmonary embolism, thrombocythaemia, thrombocytopenia, sepsis, thrombocytosis

**Cardiac:** analysis of safety databases suggests that the use of clozapine is associated with an increased risk of myocarditis (which may be fatal) especially during, but not limited to, the first month of therapy (see 7 WARNINGS AND PRECAUTIONS, Cardiovascular); atrial or ventricular fibrillation, cardiomyopathy, heart failure, mitral insufficiency, mitral valve incompetence associated with clozapine-related cardiomyopathy and myocardial infarction which may be fatal, periorbital edema, pericarditis and pericardial effusion. Very rare events of cardiac arrest, QT prolongation which may be associated with torsades de pointes, and ventricular tachycardia have been observed.

**Endocrine:** pseudophaeochromocytoma

**Eye:** narrow angle glaucoma.

**Gastrointestinal:** colitis (sometimes fatal), dysphagia, dyspepsia, fecal impaction, intestinal infarction/ischaemia (which may be fatal), intestinal obstruction/paralytic ileus, intestinal necrosis (sometimes fatal), ulceration (sometimes fatal) and perforation (sometimes fatal), parotid gland enlargement, megacolon (which may be fatal)
**General:** polyserositis

**Hepatobiliary disorders:** acute pancreatitis, cholestasis, fulminating hepatic necrosis, hepatic steatosis, hepatic necrosis, hepatitis, hepatotoxicity, hepatic fibrosis, hepatic cirrhosis, jaundice, liver disorders including those hepatic events leading to life-threatening consequences such as liver failure, liver injury, liver transplant.

**Immune system:** angioedema, leukocytoclastic vasculitis (sometimes fatal).

**Infections and infestations:** sepsis

**Investigations:** CPK elevation.

**Metabolism and nutritional:** diabetes aggravated, hypercholesterolemia, hyperglycemia, hyperosmolar coma, hypertriglyceridemia, hyperuricemia, hyponatremia, impaired glucose tolerance, ketoacidosis, new onset diabetes, obesity, weight loss

**Musculoskeletal and connective tissue:** myasthenic syndrome, rhabdomyolysis, systemic lupus erythematosus.

**Nervous system:** cholinergic syndrome, delirium, EEG abnormal, exacerbation of psychosis, myoclonus, obsessive compulsive symptoms, overdose, paresthesia, pleurothotonus, possible mild cataplexy, status epilepticus.

**Renal and urinary:** acute interstitial nephritis, nocturnal enuresis, renal failure

**Reproductive system:** priapism, retrograde ejaculation.

**Respiratory:** aspiration, pleural effusion, pneumonia and lower respiratory tract infection which may be fatal, respiratory arrest.

**Skin and subcutaneous tissue:** hypersensitivity reactions: erythema multiforme, pigmentation disorder, photosensitivity, Stevens-Johnson syndrome, vasculitis. Post market cases of Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) have been reported in association with clozapine.

9 DRUG INTERACTIONS

9.2 Drug Interactions Overview

As with other antipsychotics, caution should be exercised when CLOZARIL® (clozapine) is prescribed with medicines known to increase the QTc interval or causing electrolyte imbalance.

Clozapine is a substrate for many CYP 450 isoenzymes, in particular 1A2 and 3A4. Caution is called for in patients receiving concomitant treatment with other drugs which are either inhibitors or inducers of these enzymes.

9.3 Drug-Behavioral Interactions

CLOZARIL® may enhance the central effects of alcohol.
In cases of sudden smoking cessation, the plasma clozapine concentration may be increased, thus leading to an increase in adverse effects.

9.4 Drug-Drug Interactions

CLOZARIL® may enhance the central effects of MAO inhibitors, CNS depressants including narcotics, antihistamines, and benzodiazepines, as well as the effects of anticholinergic and antihypertensive agents.

Caution is advised with patients who are receiving (or have recently received) benzodiazepines or other psychotropic drugs, as these patients may have an increased risk of circulatory collapse accompanied by respiratory and/or cardiac arrest.

Owing to its anti-alpha-adrenergic properties, CLOZARIL® may reduce the blood pressure increasing effect of norepinephrine or other predominantly alpha-adrenergic agents and reverse the pressor effect of epinephrine.

CLOZARIL® should not be used with other agents, such as carbamazepine, having a known potential to suppress bone marrow function. In particular, the concomitant use of long-acting depot antipsychotic drugs should be avoided because these medications, which may have the potential to be myelosuppressive, cannot be rapidly removed from the body.

Concomitant use of valproic acid with CLOZARIL® may alter the plasma levels of clozapine. Rare but serious reports of seizures, including onset of seizures in non-epileptic patients, and isolated cases of delirium where CLOZARIL® was co-administered with valproic acid have been reported. These effects are possibly due to a pharmacodynamic interaction, the mechanism of which has not been determined.

Concomitant administration of drugs known to inhibit the activity of cytochrome P450 isoenzymes may increase the plasma levels of clozapine:

- Drugs known to inhibit the activity of the major isoenzymes involved in the metabolism of clozapine and with reported interactions include, cimetidine (2D6, 3A4), and erythromycin (3A4). Other potent inhibitors of CYP3A, such as azole antimycotics and protease inhibitors, could potentially also increase clozapine plasma concentrations; however, no interactions have been reported to date.

- Substantial elevation of the plasma concentration of clozapine has been reported in patients receiving the drug in combination with fluvoxamine (1A2), ciprofloxacin (1A2) and oral contraceptives (1A2, 3A4, 2C19). Smaller elevations in clozapine plasma concentrations have also been reported in patients receiving the drug in combination with other selective serotonin re-uptake inhibitors (SSRIs) such as paroxetine, sertraline, fluoxetine and citalopram (possibly a weak inhibitor of CYP1A2 and possibly the least likely among SSRIs to cause a clinically significant interaction with clozapine).

- The plasma concentration of clozapine is increased by caffeine (1A2) intake and decreased by nearly 50% following a 5-day caffeine-free period.

No clinically relevant interactions have been observed thus far with tricyclic antidepressants, or type 1c anti-arrhythmics, known to bind to cytochrome P450 2D6.
Concomitant administration of drugs known to induce cytochrome P450 enzymes may decrease the plasma levels of clozapine:

- Drugs known to induce the activity of 3A4 and with reported interactions with clozapine include, for instance, carbamazepine, phenytoin and rifampicin.
- Known inducers of 1A2 include, for instance, omeprazole and tobacco smoking. In cases of sudden smoking cessation, the plasma clozapine concentration may be increased, thus leading to an increase in adverse effects.

9.5 Drug-Food Interactions

Interactions with food have not been established.

9.6 Drug-Herb Interactions

Interactions with herbal products have not been established.

9.7 Drug-Laboratory Test Interactions

Interactions with laboratory tests have not been established.

10 CLINICAL PHARMACOLOGY

10.1 Mechanism of Action

CLOZARIL® (clozapine), a dibenzodiazepine derivative, is an atypical antipsychotic drug because its profile of binding to dopamine receptors and its effects on various dopamine-mediated behaviors differ from those exhibited by conventional antipsychotics. In contrast to conventional antipsychotics, clozapine produces little or no prolactin elevation. Clozapine exerts potent anticholinergic, adrenolytic, anti-histaminic and anti-serotoninergic activity.

Clozapine is distinguished from classical neuroleptics by its failure to induce the characteristic effects of dopamine (DA) receptor blockade, e.g., antagonism of apomorphine- or amphetamine-induced stereotyped behaviour, catalepsy, and DA receptor super sensitivity following repeated administration.

Clozapine inhibits conditioned avoidance response albeit at doses somewhat higher than those which attenuate locomotor activity. Clozapine induces hypothermia and exerts potent anti-aggressive activity against isolation-induced fighting behaviour.

Clozapine has potent anticholinergic activity as shown in in vivo (oxotremorine-induced tremors), in vitro (isolated tissue - Acetylcholine-induced contractions), and binding (3H-QNB) studies.

Clozapine has potent anti-histaminic activity as shown in in vivo (histamine - induced bronchoconstriction) and in vitro (isolated ileum - histamine-induced contractions) studies.

Clozapine has potent anti-serotoninergic activity as shown in in vivo (5-HTP-induced behaviours) and in vitro (isolated uterus - 5-HT-induced contractions) studies.

Clozapine binds to several types of receptors, especially serotoninergic (S2), alpha-adrenergic, and histaminergic (H1) receptors. It has weak dopamine receptor blocking activity at D1, D2, D3 and D5, but shows high potency for the D4 receptor.
Most neuroleptics increase dopamine (DA) turnover in the nigrostriatum to the same or greater extent than occurs in the mesolimbic system. Clozapine is atypical, in that it produces higher DA turnover in the mesolimbic than in the nigrostriatal system. Since dopamine receptor blockade in the corpus striatum is considered to be responsible for extrapyramidal symptoms observed in patients, this differential effect of clozapine may account for the low profile of extrapyramidal side effects exhibited by the drug.

10.2 Pharmacodynamics

Controlled clinical trials indicate that clozapine improves both positive and negative symptoms.

Patients on rare occasions may report an intensification of dream activity during clozapine therapy. Rapid eye movement (REM) sleep was found to be increased to 85% of the total sleep time. In these patients, the onset of REM sleep occurred almost immediately after falling asleep. As is true of more typical antipsychotic drugs, clinical EEG studies have shown that clozapine increases delta and theta activity and slows dominant alpha frequencies. Enhanced synchronization occurs, and sharp wave activity and spike and wave complexes may also develop.

10.3 Pharmacokinetics

Absorption: The absorption of orally administered clozapine is 90 to 95%. Food does not affect either the rate or the extent of absorption. Clozapine is subject to first-pass metabolism, resulting in an absolute bioavailability of 50 to 60%.

Distribution: Plasma concentrations show large inter-individual differences, with peak concentrations occurring approximately 2.5 hours (range: 1 to 6 hours) after dosing. In a dose range of 37.5 mg bid to 150 mg bid, the area under the curve (AUC) and the peak plasma concentration (C max) increase linearly in a dose-related fashion. Clozapine is approximately 95% bound to plasma proteins.

Metabolism: Clozapine is almost completely metabolized prior to excretion. Clozapine is converted to norclozapine (desmethyl clozapine) by CYP1A2 and 3A4, and to clozapine-N-oxide by 3A4, and metabolized to some extent by CYP2C19 and 2D6. Recent studies suggest that there is a significant correlation between clozapine plasma levels and clinical response. The concentrations of clozapine, and its major metabolite norclozapine, were significantly higher in responders than in nonresponders although the mean doses of clozapine did not differ between the two groups. Of the main metabolites, only norclozapine was found to be active. In patients who responded to treatment, plasma clozapine levels reached at least 350 to 370 ng/mL.

Elimination: The elimination of clozapine is biphasic with a mean terminal half-life of 12 hours (range: 6 to 30 hours, calculated from three steady-state in vivo studies). After single doses of 75 mg, the mean terminal half-life was 7.9 hours; it increased to 14.2 hours when steady-state conditions were reached by administering daily doses of 75 mg for at least 7 days. Only trace amounts of unchanged drug are detected in the urine and feces. Approximately 50% of the administered dose is excreted as metabolites in the urine and 30% in the feces.
11 STORAGE, STABILITY AND DISPOSAL

Store at room temperature (15-30°C).
Store in original container.

12 SPECIAL HANDLING INSTRUCTIONS

There are no special instructions in handling CLOZARIL®.
PART II: SCIENTIFIC INFORMATION

13 PHARMACEUTICAL INFORMATION

Drug Substance

Proper name: Clozapine

Chemical name: 8-Chloro-11-(4-methyl-1-piperazinyl)-5H-dibenzo[b,e][1,4]-diazepine

Molecular formula: C_{18}H_{19}ClN_{4}

Molecular mass: 326.83

Structural formula:

![Structural formula of clozapine]

Physicochemical properties: Clozapine is a yellow, crystalline powder with a melting range of 182.0°-186.0°C. The values for pKa (I) and pKa (II) are 3.69 and 7.57 respectively. At 25°C, the solubility of clozapine is <0.01% in water and >20% in chloroform.

14 CLINICAL TRIALS

Clinical Trial Data on Suicidal Behaviour (InterSePT Study)
The International Suicide Prevention Study (InterSePT) Study ABA 451 was a prospective, open-label randomized, international, parallel-group comparison of CLOZARIL® vs. ZYPREXA* (olanzapine) of two years duration, with approximately 490 patients per treatment group.

14.1 Trial Design and Study Demographics

Patients were diagnosed with schizophrenia or schizoaffective disorder using DSM-IV criteria and meeting at least one of the following criteria in order to be deemed at high risk for suicide: a) a suicide attempt, or hospitalization to prevent an attempt, within the last three years; or b) moderate to severe suicidal ideation with either a depressive component or command hallucinations, within the last week. One fourth (27%) of the patient population was considered "treatment-resistant".

Due to the high-risk nature of the study population, the principal investigators (PIs) were permitted to treat patients as they judged necessary, including concomitant medications, non-drug treatments, and hospitalizations. Both the PIs and the patients were aware of the treatment group assignment.

* All trademarks and registered trademarks are the property of their respective owners.
**Efficacy Measures**

The primary efficacy measure was time to the first occurrence of either a Type I or Type II event.

The unblinded PIs were responsible for identifying Type I events: a suicide attempt, or the judgement of need for hospitalization/increased surveillance to prevent an attempt. In the case of the Type I events, all relevant information from the PIs was blinded and forwarded to a blinded group of experts (the Suicide Monitoring Board) for final confirmation of each potential Type I event. Blinded psychiatrists, who assessed the patients at pre-determined intervals, were responsible for identifying Type II events: "much worsening" or "very much worsening" from baseline in the Clinical Global Impression of Severity of Suicidality-Blinded Psychiatrist (CGI-SS-BP) scale.

**14.2 Study Results**

Analysis using the Cox's proportional hazard regression model demonstrates that within the context of the InterSePT trial there was a 26% reduced risk for a suicide attempt or hospitalization to prevent suicide (Type 1 event) for CLOZARIL®-treated patients compared to ZYPREXA* treated-patients (p=0.02, hazard ratio 0.74 [95% C.I.:0.57, 0.96]).

Factors that preclude regulatory endorsement of an indication for CLOZARIL® for the risk of recurrent suicidal behavior in patients with schizophrenia or schizoaffective disorder:

1. The heavy reliance of the endpoints on clinical judgement, when combined with the fact that the principal investigators were not blinded to the treatment group, creates the potential for bias in the results.

2. Separate indications for the domain of recurrent suicidal behavior versus that of psychosis require a conclusion that the two domains are independent; currently, there is insufficient evidence to allow such a conclusion.

3. The usual concerns with generalizability of study results to individual patients in clinical practice are magnified in this therapeutic area. Given that schizophrenia is associated with long-term increased risk of suicide, the two-year duration of the study limits generalizability. Many patients in this study had multiple suicide risk factors; the variable and dynamic nature of risk and protective factors, and the unpredictability of interaction with unique life circumstances also limit generalizability, as do the unusual efforts made in the study to prevent a suicide attempt, including frequent patient-clinician contact.

4. Because decisions about concomitant treatment were made by unblinded PIs, the post-hoc finding that the CLOZARIL® group received significantly less psychotropic medication than did the ZYPREXA* group is not readily interpretable.

5. This is the sole prospective randomized trial.

**Conclusion**

Under the currently approved Canadian indication, CLOZARIL® is already available to a substantial percentage of psychotic patients at risk of suicide, given the frequency of tolerability issues and the fact that a complete response to an anti-psychotic is rare. The InterSePT study is a source of further information with regards to these patients.
While the InterSePT results are hypothesis-generating, they fail to provide sufficient evidence to support the safety and efficacy of the use of CLOZARIL® in patients who are naive to anti-psychotics or have schizoaffective disorder.

15 MICROBIOLOGY

No microbiological information is required for this drug product.

16 NON-CLINICAL TOXICOLOGY

General Toxicity
The acute toxicity of clozapine is as follows:

Table 5 - Acute Toxicity of Clozapine

<table>
<thead>
<tr>
<th>Species</th>
<th>Sex</th>
<th>Route</th>
<th>LD$_{50}$ (mg/kg)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mouse</td>
<td>M,F</td>
<td>IV</td>
<td>61</td>
</tr>
<tr>
<td>Mouse</td>
<td>M,F</td>
<td>IP</td>
<td>90</td>
</tr>
<tr>
<td>Mouse</td>
<td>M</td>
<td>Oral</td>
<td>210</td>
</tr>
<tr>
<td>Mouse</td>
<td>F</td>
<td>Oral</td>
<td>190</td>
</tr>
<tr>
<td>Rat</td>
<td>M,F</td>
<td>IV</td>
<td>58</td>
</tr>
<tr>
<td>Rat</td>
<td>M</td>
<td>IM</td>
<td>228</td>
</tr>
<tr>
<td>Rat</td>
<td>F</td>
<td>IM</td>
<td>198</td>
</tr>
<tr>
<td>Rat</td>
<td>M</td>
<td>Oral</td>
<td>325</td>
</tr>
<tr>
<td>Rat</td>
<td>F</td>
<td>Oral</td>
<td>225</td>
</tr>
<tr>
<td>Guinea Pig</td>
<td>M</td>
<td>Oral</td>
<td>510</td>
</tr>
<tr>
<td>Guinea Pig</td>
<td>F</td>
<td>Oral</td>
<td>681</td>
</tr>
<tr>
<td>Dog</td>
<td>M,F</td>
<td>Oral</td>
<td>145</td>
</tr>
</tbody>
</table>

Long-Term Toxicity

Table 6 - Long Term Toxicity of Clozapine

<table>
<thead>
<tr>
<th>Species</th>
<th>Duration</th>
<th>Route</th>
<th>Dose (mg/kg/d)</th>
<th>Findings</th>
</tr>
</thead>
<tbody>
<tr>
<td>Rat</td>
<td>26-week</td>
<td>Oral gavage</td>
<td>10, 20, 40</td>
<td>10 mg/kg/day: slight increase in liver weights in the males. 20, 40 mg/kg/day: sedation during early weeks; aggression during the later weeks; somewhat impaired weight gain; absolute and relative liver weights slightly increased; fore stomach slightly dilated in males.</td>
</tr>
<tr>
<td>Rat</td>
<td>100-week</td>
<td>Oral feed</td>
<td>0, 15, 31, 74</td>
<td>During the study, a dose- and time-dependent occurrence of increased lipopigment was observed in various organs. 15 mg/kg/d: pigment seen in thyroid, heart and brain at terminal examination (100 weeks), not associated with significant adverse changes. 31 mg/kg/day: reddened urine (probably due to a metabolite) 31, 74 mg/kg/day: increased lipopigment in the thyroid, brain, kidney, liver, heart, spleen and skeletal muscle of animals dying or sacrificed after one year.</td>
</tr>
<tr>
<td>Species</td>
<td>Duration</td>
<td>Route</td>
<td>Dose (mg/kg/d)</td>
<td>Findings</td>
</tr>
<tr>
<td>--------------</td>
<td>---------------</td>
<td>-------</td>
<td>----------------</td>
<td>---------------------------------------------------------------------------------------------------------------------------------------</td>
</tr>
<tr>
<td>Rat</td>
<td>24-month (108 weeks)</td>
<td>Oral feed</td>
<td>0, 3, 10, 35</td>
<td>Mortality comparable to controls at all time intervals. With the exception of lipofuscin pigmentation similar to that observed in the 100-week oral toxicity study there was no evidence that the treatments had affected the occurrence of diseases anticipated to occur spontaneously in laboratory rats.</td>
</tr>
<tr>
<td>Mouse</td>
<td>78-week</td>
<td>Oral feed</td>
<td>40 (75 after wk 32, in half of group)</td>
<td>Occasional skin lesions during early weeks of treatment in up to 40% of the mice (including controls) of unknown etiology (treated for short periods with antibiotic and antimycotic drugs). Clinical pathology results were unremarkable except for slightly increased serum glutamic oxaloacetic transaminase levels in treated mice at week 78. No evidence of hepatotoxicity in liver histology.</td>
</tr>
<tr>
<td>Beagle Dogs</td>
<td>13-weeks</td>
<td>Oral capsules</td>
<td>0, 5, 10, 20</td>
<td>All doses: dose-dependent sedation, muscular relaxation, miosis, lacrimation, salivation, muscular tremors, prolapse of nictitating membranes, irritability and emesis, all disappearing within 12 hours after drug administration except salivation, persisting up to 24 hours. No toxicological changes. Toxicological changes: increased liver weight in some treated dogs compared with controls (non-dose-dependent). One female (10 mg/kg/d) died after 25 days of treatment, due to acute pneumonia (not medication-related). No other deaths occurred at any dose level.</td>
</tr>
<tr>
<td>Beagle Dogs</td>
<td>1 year</td>
<td>Oral capsules</td>
<td>Wk -9: Increasing from 20 – 90 Wk 9-13: 90 + 8 wk recovery for half 20 - 30 mg/kg/day: slight paresis, prolapse of the nictitating membrane, salivation, tremor and distinct dacryorrhea, progressively accentuated at increasing doses. Increasing doses: miosis, unnatural posture, tachypnea and aggression; convulsions and ataxia (2 dosages), all disappearing within 2 wk drug discontinuation. ECG: decreased heart rate, prolonged QT intervals and twin-peaked T-waves in some leads, disappearing within 4 weeks after drug discontinuation. No other drug-induced changes found on clinical and postmortem examinations, with the possible exception of increased kidney weights. Microscopic examinations were unremarkable. 90 mg/kg/d is ~60% of acute LD50.</td>
<td></td>
</tr>
<tr>
<td>Species</td>
<td>Duration</td>
<td>Route</td>
<td>Dose (mg/kg/d)</td>
<td>Findings</td>
</tr>
<tr>
<td>--------------</td>
<td>----------</td>
<td>------------</td>
<td>----------------</td>
<td>------------------------------------------------------------------------------------------------------------------------------------------</td>
</tr>
<tr>
<td>Rhesus Monkey</td>
<td>104-wk</td>
<td>Oral caps</td>
<td>3, 20 (up to 30 in early weeks)</td>
<td>3 mg/kg/d: slight transient clinical signs (sedation and ptosis on day 1) and minor hematologic changes in the early weeks (slight falls in red and white blood cell counts without development of anemia or leukopenia). ECG: slightly prolonged QT intervals in individual monkeys at sporadic intervals, mostly in the first year. &quot;No-toxic effect&quot; level for the monkey. 20 mg/kg/d: sedation, ptosis and salivation; impaired weight gain; slight depressions of red and white cell counts (no cases of anemia or leukopenia). ECG: similar to low dose, although decreased incidence during year 2. 1-year post-mortem: slightly increased lipopigment deposition in myocardial fibres 2-year post-mortem: distinct brown discoloration of heart and urinary bladder mucosa associated with pigment deposition. Similar pigment was also seen microscopically in the neurons of the CNS and the mucosa of the gallbladder; slightly increased splenic weights; no specific organ toxicity seen.</td>
</tr>
</tbody>
</table>

**Carcinogenicity**

No evidence of carcinogenicity was seen in the 100-week and 24-month rat toxicity studies or the 78-week mouse carcinogenicity study described above, or in a second 18-month mouse study of clozapine 6, 21, and 61 mg/kg/d.

**Genotoxicity**

No evidence of mutagenic effects of clozapine was detected in four assays: 1. Ames Salmonella; 2. DNA repair synthesis (UDS) in vitro rat hepatocytes; 3. V79 Chinese hamster cells in vitro; and 4. In vivo mouse micronucleus.

**Reproductive and Developmental Toxicology**

**Teratology:** Pregnant rats and rabbits were given clozapine 0, 20 and 40 mg/kg/day orally during organogenesis.

Clozapine had no apparent effect on the maternal, litter or fetal parameters. In rabbits, treatment attenuated weight gain during drug administration, which was not compensated for during the remainder of pregnancy. Nevertheless, no drug-related change in pregnancy, litter, or fetal data was observed, apart from a slight reduction in mean fetal weights (within normal limits).

**Fertility:** Male and female rats were treated before mating with clozapine 0, 20 and 40 mg/kg/day by gavage for 70 and 14 days, respectively. On day 13 of pregnancy half of the dams were sacrificed. Their genital tract and the condition of the fetuses were inspected. The remaining dams were allowed to litter and the young were sacrificed on day 21 postpartum and examined for abnormalities.

At the end of the treatment period, treated males, at both dose levels, had impaired weight gain as compared to the controls. Sedation was seen at 40 mg/kg/day, and excitation at 20 mg/kg/day. Fertility was not impaired. Pregnancy, fetal and postnatal development of the young were normal throughout the study.
In the females, the 2-week treatment period had no adverse effect on weight gain. The pharmacological effects observed were similar to those seen in the males. Pregnancy rate was remarkably high in the 40 mg/kg group but was associated with a slightly increased number of intrauterine deaths. No abnormalities were observed in fetuses or newborn animals. Birth and postnatal development were normal throughout the study.

**Perinatal:** Mated female rats were given clozapine by gavage at doses of 20 and 40 mg/kg/day over the last third of pregnancy until day 21 post-partum. Controls received water. Observations of the fetuses were made at birth and during the postnatal period.

A dose-dependent impairment of weight gain was apparent in the dams. With 40 mg/kg/day there was actually a weight loss. Litter size and litter weights were within normal limits, although a slight dose-dependent reduction was seen. Survival rates and mean weights of the offspring were reduced by the end of lactation compared to that of the controls. The offspring showed evidence of increased excitability.

**Generation Study:** The offspring of the three groups of the above study (controls, 20 and 40 mg/kg/day) were allowed to reach sexual maturity and mated, six possible combinations between groups being used (control males with 40 mg/kg females, control males with 20 mg/kg females, 40 mg/kg males with control females, 20 mg/kg males with control females, 20 mg/kg males with same dose females, 40 mg/kg males with same dose females). Pregnancy rates and litter data as well as the postnatal development of the F2-generation were studied.

In none of the 6 groups was a deviation from normal values detected, nor was any intra-group difference noted. From these results, it may be concluded that clozapine administration had no effect on the F2-generation.

**Other Studies**
In several test systems employing animal bone marrow cells, clozapine, as well as certain other drugs with a potential to cause neutropenia were shown to have a suppressant effect on cell division. However, the relevance of these models for predicting potential bone marrow toxicity remains to be fully established.
PATIENT MEDICATION INFORMATION
READ THIS FOR SAFE AND EFFECTIVE USE OF YOUR MEDICINE

PrCLOZARIL®
Clozapine Tablets

Read this carefully before you start taking CLOZARIL® and each time you get a refill. This leaflet is a summary and will not tell you everything about this drug. Talk to your healthcare professional about your medical condition and treatment and ask if there is any new information about CLOZARIL®.

What is CLOZARIL® used for?
CLOZARIL® is a drug for the treatment of symptoms of schizophrenia. It is used in adults over 18 years of age who do not respond to, or who experience serious side-effects with other drugs used for the same purpose.

Important Information:
CLOZARIL® is only available through a distribution system.

Why does my doctor need my consent?
Clozapine is available from many different suppliers and each supplier has a different monitoring system to ensure patient safety. If your doctor and/or pharmacist (with your doctor’s approval) change the brand of clozapine you are taking, you will be moved to that supplier’s monitoring system. Your doctor needs your consent so that your supplier can:

- Access your past white blood cell count results from other suppliers
- See if you have experienced a decrease in your white blood cell count in the past while taking clozapine

Serious Warnings and Precautions

- **Severe neutropenia (Agranulocytosis)** (decrease in white blood cells): CLOZARIL® can cause a life-threatening decrease in your white blood cell count, which can lead to serious infection and death. Due to this risk, you must undergo regular blood testing if you are taking CLOZARIL®. Your doctor will enroll you in a monitoring system to make sure your blood tests are done regularly (see What is CLOZARIL® used for and Other warnings you should know about for more information).

- **Heart problems:** Myocarditis (inflammation of the heart muscle) and cardiomyopathy (heart muscle disease) have occurred in people using CLOZARIL®. These reactions can be fatal. If you think you are experiencing a problem with your heart, get medical help **right away** (see the Serious side effects and what to do about them table below for a list of symptoms).

- **There** is a higher risk of death when medicines like CLOZARIL® are used in elderly patients with dementia. CLOZARIL® is **not** for use in elderly patients with dementia.

Why is personal information such as my initials, birth date, gender and health card number being collected and used for identification purposes?
Since this information is specific to you, it helps to ensure that your test results are not mixed up with those of another person. Using this information also avoids the need to use your full name, which protects your privacy.

Can my personal information be used for other purposes?
No. Your information will only be used to make sure that you are properly monitored while using any brand of clozapine.
Where can I find information on the protection of health-related personal information in the private sector?
Information on this topic can be found on the website of Industry Canada, at the following address:

How does CLOZARIL® work?
CLOZARIL® belongs to a group of medicines called antipsychotic drugs. Antipsychotic medications affect dopamine and serotonin (chemicals found in the brain) that allow for the communication between your nerve cells. Exactly how this medication works is not known. However, it seems that CLOZARIL® improves the balance of dopamine and serotonin in your body.

What are the ingredients in CLOZARIL®?
Medicinal ingredients: clozapine
Non-medicinal ingredients: colloidal silicon dioxide, lactose, magnesium stearate, povidone, starch and talc.

CLOZARIL® comes in the following dosage forms:
Tablets; 25 mg, 50 mg, 100 mg and 200 mg

Do not use CLOZARIL® if:
- You are allergic to clozapine or to any of the other ingredients listed in “What are the ingredients in CLOZARIL®”.
- You are unable to undergo regular blood tests
- You have ever had a low number of white blood cells, except if this was following a treatment for cancer (chemotherapy)
- You have or have ever had bone marrow disease or are taking medication to suppress bone marrow function
- You have or have ever had a disease that affect your blood cell formation
- You have liver disease
- You have kidney disease or kidney failure
- You have heart problems such as myocarditis, cardiomyopathy, or heart failure
- You have severe nervous system depression
- You have uncontrolled seizures
- You have or have ever had a “paralytic ileus”, severe constipation, an obstruction of the bowel or any other condition which has affected your large bowel

To help avoid side effects and ensure proper use, talk to your healthcare professional before you take CLOZARIL®. Talk about any health conditions or problems you may have, including if you:
- Have a fever or an infection
- Suffer from enlargement of the prostate
- Have a history of seizures (e.g., epilepsy)
- Have glaucoma (an eye condition)
- Have or have a family history of diabetes
- Have risk factors for developing blood clots such as:
  - a family history of blood clots
  - being over the age of 65
  - smoking
  - being overweight
  - having a recent major surgery (such as hip or knee replacement)
  - not being able to move due to air travel or other reasons
  - taking oral birth control (“The Pill”)
- Have a history of colon disease or lower abdominal surgery
- You have stable pre-existing liver disorder
- Have heart disease or family history of abnormal conduction in the heart called “prolongation of the QT interval”
- Have low blood pressure
- Have a fast heart rate (tachycardia)
- Have had a stroke
- Have or have had lung disease
- Have Alzheimer's disease
- Have a condition called dementia
- Are pregnant or planning to become pregnant
- Are breast-feeding or planning to breast-feed, you should not breast-feed if you are taking CLOZARIL®
- Have a history of or are at risk of sleep apnea (a sleep disorder where your breathing is interrupted during sleep)
- Are at risk for aspiration pneumonia

Tell your doctor or pharmacist what your coffee intake is and if you smoke. Abrupt changes in your habits may change the effect of CLOZARIL®.

Other warnings you should know about:

**Effects on Newborns:** In some cases, babies born to a mother taking CLOZARIL® during pregnancy may have symptoms that are severe and require the newborn to go to the hospital. Sometimes, the symptoms may resolve on their own. Get emergency medical help for your newborn, if they:
- Have trouble breathing
- Are overly sleepy
- Have muscle stiffness or floppy muscles (like a rag doll)
- Are shaking
- Are having difficulty feeding

**Falls:** CLOZARIL® can cause you to feel sleepy or dizzy and can affect your balance. This increases your risk of falling, which can cause fractures or other fall related-injuries, especially if you:
- Take sedatives
- Consume alcohol
- Are elderly
- Have a condition that causes weakness or frailty

**Monitoring and Tests:** Your doctor will do tests before you start treatment with CLOZARIL® and while you are taking it. These tests may include:
- Blood tests to monitor:
  - White blood cell count
  - Blood sugar (glucose) levels in your body
  - Fat (lipid) levels in your body
  - Liver function
- Tests to monitor body weight as CLOZARIL® may cause you to gain weight

**Why is the testing of your blood by your doctor necessary?**
In rare cases, CLOZARIL® can cause a life-threatening decrease of white blood cells. To ensure that your body has enough white blood cells, it is important to have regular blood testing done.

Blood testing must be done:
- Weekly during the first 26 weeks of treatment with clozapine. The risk for developing a deficiency of white blood cells is highest during this time.
- Following this initial period, you and your doctor will evaluate the possibility of doing your blood tests to two-week intervals for the next 26 weeks.
- Following 52 weeks of continuous therapy, blood tests could be performed every 4 weeks if your clinical condition permits it.

Regular blood testing must be done for as long as you are taking CLOZARIL®.
Tell your doctor immediately at the first signs of a cold, flu-like symptoms, fever, sore throat, weakness, or any other signs of infection. Your doctor may check your blood cell count and take further measures if necessary.

**Driving and using machines:** Due to the risk of convulsions during CLOZARIL® treatment, you should avoid activities where a sudden loss of consciousness could cause risk to yourself or others (e.g., driving, using machines, swimming, climbing).

**CLOZARIL® can cause serious side effects including:**
- Neuroleptic Malignant Syndrome (NMS) a condition that affects the nervous system
- Tardive Dyskinesia (TD) a condition that affects your movements that may be irreversible
- Severe skin reactions that can be life-threatening such as Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), drug reaction with eosinophilia and systemic symptoms (DRESS) and acute generalized exanthematous pustulosis (AGEP)

See the **Serious side effects and what to do about them** table below for more information on these and other serious side effects.

**Tell your healthcare professional about all the medicines you take, including any drugs, vitamins, minerals, natural supplements or alternative medicines.**

The following may interact with CLOZARIL®:
- Carbamazepine
- Phenytoin
- Omeprazole
- Rifampicin
- Erythromycin
- Cimetidine
- Valproic acid
- Medicines used to treat fungal infections such as fluconazole, miconazole, clotrimazole
- Medicines use to treat depression such as fluvoxamine, paroxetine, sertraline, fluoxetine, citalopram
- Ciprofloxacin
- Caffeine
- Tobacco smoking
- Narcotics
- Benzodiazipines
- Norepinephrine
- Epinephrine
- MAO (monoamine oxidase) inhibitors
- Any drugs used to suppress bone marrow function
- Oral birth control medicines
- Medicines used to treat high blood pressure
- Medicines used to treat allergies
- Medicines used to treat psychotic disorders
- Medicines that cause constipation
- Medicines called "anticholinergic agents"
- Alcohol

**How to take CLOZARIL®:**
- Take exactly as your healthcare professional has told you to
- If you think your dose is too weak or too strong, talk to your doctor
- Try to take CLOZARIL® at the same time each day, this will help you remember to take your medicine
• Tablets can be taken whole or crushed

Usual dose:
The usual starting dose is 12.5 mg (one half of a 25 mg tablet) once or twice on the first day. Your doctor will then slowly increase your dose depending on how severe your disease is and how well your body tolerates the medicine. Your doctor will decide the best dose for you. Take CLOZARIL® exactly as your healthcare professional has told you to.

Do not stop taking CLOZARIL® suddenly as it may cause unwanted side effects. If you need to stop taking CLOZARIL®, discuss with your doctor how to slowly stop the medication

Overdose:
If you think you, or a person you are caring for, have taken too much CLOZARIL®, contact a healthcare professional, hospital emergency department or regional poison control centre immediately, even if there are no symptoms.

Missed Dose:
If you miss a dose of CLOZARIL®, and remember within two hours, take the dose right away. Otherwise, skip the missed dose and continue with your regular dosing schedule. Do not take double doses. If you stop taking CLOZARIL® for more than two days, contact your doctor for dosing instructions, do not re-start taking the drug.

What are possible side effects from using CLOZARIL®?
These are not all the possible side effects you may have when taking CLOZARIL®. If you experience any side effects not listed here, contact your healthcare professional.

• Headache
• Fever
• Confusion
• Drowsiness or feeling sleepy
• Dizziness
• Blurred vision
• Lightheadedness or fainting
• Falls and fractures
• Stuffy nose
• Increased saliva
• Dry mouth
• Trouble swallowing
• Sweating
• Heartburn
• Stomach pain
• Nausea
• Vomiting
• Constipation
• Diarrhea
• Weight gain
• Urinating less
• Nighttime bedwetting
• Abnormal ejaculation (dry orgasm)
• Stuttering or slurred speech
• Obsessive thoughts and behaviours
• Having trouble reading
• Uncontrolled bending of the body to one side
• Feeling restless or not being able to stay still
• Muscle weakness, stiffness or pain
- Joint pain
- Swelling of the cheeks
- Rash on the body or face
- Itchy skin
- Patches of skin discoloration

### Serious side effects and what to do about them

<table>
<thead>
<tr>
<th>Symptom / effect</th>
<th>Talk to your healthcare professional</th>
<th>Stop taking drug and get immediate medical help</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Very common</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>New or worsening constipation</td>
<td></td>
<td>✔</td>
</tr>
<tr>
<td><strong>Common</strong></td>
<td></td>
<td>✔</td>
</tr>
<tr>
<td>Eosinophilia (increased numbers of certain white blood cells): abdominal pain, rash, weight loss, wheezing</td>
<td></td>
<td>✔</td>
</tr>
<tr>
<td>Hypotension (low blood pressure): dizziness, fainting, light-headedness, blurred vision, nausea, vomiting, fatigue (may occur when you go from lying or sitting to standing up)</td>
<td></td>
<td>✔</td>
</tr>
<tr>
<td>Neuroleptic Malignant Syndrome (NMS): pronounced muscle stiffness or inflexibility with high fever, rapid or irregular heartbeat, sweating, state of confusion or reduced consciousness.</td>
<td></td>
<td>✔</td>
</tr>
<tr>
<td>Seizures: uncontrollable shaking with or without loss of consciousness.</td>
<td></td>
<td>✔</td>
</tr>
<tr>
<td>Sudden weakness or numbness of the face, arms or legs and speech or vision problems.</td>
<td></td>
<td>✔</td>
</tr>
<tr>
<td><strong>Uncommon</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Myocardial infarction (heart attack): pressure or squeezing pain between the shoulder blades, in the chest, jaw, left arm or upper abdomen, shortness of breath, dizziness, fatigue, light-headedness, clammy skin, sweating, indigestion, anxiety, feeling faint and possible irregular heartbeat.</td>
<td></td>
<td>✔</td>
</tr>
<tr>
<td>Signs of infection: fever, severe chills, sore throat or mouth ulcers (sign of decreased white blood cells), nausea, vomiting, diarrhea, generally feeling unwell.</td>
<td></td>
<td>✔</td>
</tr>
<tr>
<td>Tardive Dyskinesia (TD): muscle twitching or unusual/abnormal movement of the face or tongue or other parts of your body.</td>
<td></td>
<td>✔</td>
</tr>
<tr>
<td><strong>Rare</strong></td>
<td></td>
<td>✔</td>
</tr>
<tr>
<td>Anemia (low level of red blood cells): fatigue, pale skin, headache, shortness of breath, dizziness, weakness, difficulty sleeping.</td>
<td></td>
<td>✔</td>
</tr>
<tr>
<td>Diabetes (high sugar levels in the blood): Excessive thirst or eating, dry mouth and passing large amounts of urine, unexplained weight loss, poor wound healing, infections.</td>
<td></td>
<td>✔</td>
</tr>
<tr>
<td>Dysphagia: difficulty swallowing that can cause food or liquid to get into your lungs, problems with your esophagus.</td>
<td></td>
<td>✔</td>
</tr>
<tr>
<td>Heart Problems – Myocarditis and/or Pericarditis, Cardiomyopathy (inflammation of the heart muscle and/or lining around the heart; heart muscle disease): abnormal heartbeat, chest pain that may resemble a heart attack, fatigue, fever and other signs of infection including headache, muscle aches, sore throat, diarrhea, or rashes, joint pain or swelling, leg swelling, shortness of breath.</td>
<td></td>
<td>✔</td>
</tr>
<tr>
<td>Symptom / effect</td>
<td>Talk to your healthcare professional</td>
<td>Stop taking drug and get immediate medical help</td>
</tr>
<tr>
<td>---------------------------------------------------------------------------------</td>
<td>--------------------------------------</td>
<td>-----------------------------------------------</td>
</tr>
<tr>
<td>** Liver Disorder: ** yellowing of the skin or eyes, dark urine, abdominal pain, nausea, vomiting, loss of appetite.</td>
<td>Only if severe</td>
<td>In all cases</td>
</tr>
<tr>
<td><strong>Pancreatitis</strong> (inflammation of the pancreas): upper abdominal pain, fever, rapid heartbeat, nausea, vomiting, tenderness when touching the abdomen.</td>
<td></td>
<td>✓</td>
</tr>
<tr>
<td><strong>Signs of respiratory tract infection or pneumonia</strong> such as fever, coughing, difficulty breathing or wheezing.</td>
<td></td>
<td>✓</td>
</tr>
<tr>
<td><strong>Venous thromboembolism</strong> (blood clot in a vein or artery): pain, tenderness or swelling in your arm or leg, skin that is red or warm, coldness, tingling or numbness, pale skin, muscle pain or spasms, weakness.</td>
<td></td>
<td>✓</td>
</tr>
<tr>
<td><strong>VERY RARE</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Allergic reaction</strong>: difficulty swallowing or breathing, wheezing, feeling sick to your stomach and throwing up, hives or rash, swelling of the face, lips, tongue or throat.</td>
<td></td>
<td>✓</td>
</tr>
<tr>
<td><strong>Fast and irregular heartbeat that persists when you are at rest, possibly with shortness of breath and swelling of the feet or legs.</strong></td>
<td></td>
<td>✓</td>
</tr>
<tr>
<td><strong>Feeling sick, vomiting with severe/prolonged constipation</strong></td>
<td></td>
<td>✓</td>
</tr>
<tr>
<td><strong>Increased liver enzymes in the blood</strong>: dark urine, fatigue, loss of appetite, yellowing of the skin or eyes.</td>
<td></td>
<td>✓</td>
</tr>
<tr>
<td><strong>Nephritis</strong> (inflammation of the kidney): pelvic pain, pain or burning while urinating, frequent need to urinate, cloudy urine, blood or pus in the urine. Swelling especially face or legs.</td>
<td></td>
<td>✓</td>
</tr>
<tr>
<td><strong>Priapism</strong>: Long-lasting (greater than 4 hours in duration) and usually painful erection of the penis.</td>
<td></td>
<td>✓</td>
</tr>
<tr>
<td><strong>Severe skin reactions</strong>: fever, severe rash, swollen lymph glands, flu-like feeling, blisters and peeling skin that may start in and around the mouth, nose, eyes and genitals and spread to other areas of the body, yellow skin or eyes, shortness of breath, dry cough, chest pain or discomfort, feeling thirsty, urinating less often, less urine</td>
<td></td>
<td>✓</td>
</tr>
<tr>
<td><strong>Thrombocytopenia</strong> (low blood platelets): bruising or bleeding for longer than usual if you hurt yourself, fatigue and weakness.</td>
<td></td>
<td>✓</td>
</tr>
<tr>
<td><strong>Thrombocytosis</strong> (high blood platelets): headache, dizziness or lightheadedness, chest pain, weakness, fainting, temporary vision change, numbness or tingling of the hands and feet.</td>
<td></td>
<td>✓</td>
</tr>
</tbody>
</table>

If you have a troublesome symptom or side effect that is not listed here or becomes bad enough to interfere with your daily activities, tell your healthcare professional.
Reporting Side Effects

You can report any suspected side effects associated with the use of health products to Health Canada by:

- Visiting the Web page on Adverse Reaction Reporting ([https://www.canada.ca/en/health-canada/services/drugs-health-products/medeffect-canada.html](https://www.canada.ca/en/health-canada/services/drugs-health-products/medeffect-canada.html)) for information on how to report online, by mail or by fax; or
- Calling toll-free at 1-866-234-2345.

*NOTE: Contact your health professional if you need information about how to manage your side effects. The Canada Vigilance Program does not provide medical advice.*

Storage:

- Store at room temperature (15-30° C).
- Store in original container.
- Do not use after the expiry date shown on the bottle.

Keep out of the reach and sight of children.

If you want more information about CLOZARIL®:

- Talk to your healthcare professional

This leaflet was prepared by HLS Therapeutics Inc.
Etobicoke, Ontario M9W 6L2
Canada

Last Revised: May 31, 2021
CLOZARIL® is a registered trademark of Novartis Pharmaceuticals Corporation.